



PC/EP 03/14867

11.02.04



INVESTOR IN PEOPLE

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b):

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

RECEIVED

03 MAR 2004

WIPO

PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.


BEST AVAILABLE COPY

Signed

Andrew

Dated

4 December 2003





1/77 / E P 0414 067
2.04

1/77

20DEC02 E773715-1 001030
P01/7700 0.00-0230165.3

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office
Cardiff Road
Newport
Gwent NP9 1RH

1. Your reference

~~REHILAB/PS~~ APB/P33168

2. Patent application number

(The Patent Office will fill in his part)

0230165.3

24 DEC 2002

3. Full name, address and postcode of the or of each applicant (underline all surnames)

Patents ADP number (if you know it)

473587003

If the applicant is a corporate body, give the country/state of its incorporation

Glaxo Group Limited
Glaxo Wellcome House, Berkeley Avenue,
Greenford, Middlesex UB6 0NN, Great Britain

United Kingdom

4. Title of the invention

COMPOUNDS

5. Name of your agent (if you have one)

Corporate Intellectual Property

"Address for service" in the United Kingdom to which all correspondence should be sent

(including the postcode)

Patents ADP number (if you know it)

GlaxoSmithKline
Corporate Intellectual Property (CN9 25.1)
980 Great West Road
BRENTFORD
Middlesex TW8 9GS

807255006

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or each of these earlier applications and (if you know it) the or each application number

Country	Priority application number (if you know it)	Date of filing (day / month / year)
---------	---	--

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application	Date of filing (day / month / year)
-------------------------------	--

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer yes if:

- a) any applicant named in part 3 is not an inventor, or
 - b) there is an inventor who is named as an applicant, or
 - c) any named applicant is a corporate body
- See note (d)

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form.
Do not count copies of the same document

Continuation sheets of this form —
Description 53
Claim(s) 1
Abstract —
Drawings —

10. If you are also filing any of the following, state how many against each item.

Priority Documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*)

Request for substantive examination (*Patents Form 10/77*)

Any other documents
(please specify)

11.

We request the grant of a patent on the basis of this application

Signature R E H Hackett Date 23-Dec-02
R E H Hackett

12. Name and daytime telephone number of person to contact in the United Kingdom

R E H Hackett 01438 768534
or Anthony Green 01438 762055

Warning

After an application for a Patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission unless an application has been filed at least six weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- For details of the fee and ways to pay please contact the Patent Office.


COMPOUNDS

The present invention relates to pyrazolopyridine compounds, processes for their preparation, intermediates usable in these processes, and pharmaceutical compositions containing the compounds. The invention also relates to the use of the pyrazolopyridine compounds in therapy, for example as inhibitors of phosphodiesterases (PDE) and/or for the treatment and/or prophylaxis of inflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma or allergic rhinitis.

- 10 US 3,979,399, US 3,840,546, and US 3,966,746 (E.R.Squibb & Sons) disclose 4-amino derivatives of pyrazolo[3,4-b]pyridine-5-carboxamides wherein the 4-amino group NR_3R_4 can be an acyclic amino group wherein R_3 and R_4 may each be hydrogen, lower alkyl (e.g. butyl), phenyl, etc.; NR_3R_4 can alternatively be a 3-6-membered heterocyclic group such as pyrrolidino, piperidino and piperazino. The compounds are disclosed as
15 central nervous system depressants useful as ataractic, analgesic and hypotensive agents.

- US 3,925,388, US 3,856,799, US 3,833,594 and US 3,755,340 (E.R.Squibb & Sons) disclose 4-amino derivatives of pyrazolo[3,4-b]pyridine-5-carboxylic acids and esters. The 4-amino group NR_3R_4 can be an acyclic amino group wherein R_3 and R_4 may each
20 be hydrogen, lower alkyl (e.g. butyl), phenyl, etc.; NR_3R_4 can alternatively be a 5-6-membered heterocyclic group in which an additional nitrogen is present such as pyrrolidino, piperidino, pyrazolyl, pyrimidinyl, pyridazinyl or piperazinyl. The compounds are mentioned as being central nervous system depressants useful as ataractic agents or tranquilisers, as having antiinflammatory and analgesic properties. The
25 compounds are mentioned as increasing the intracellular concentration of adenosine-3',5'-cyclic monophosphate and for alleviating the symptoms of asthma.

- Japanese laid-open patent application JP-2002-20386-A (Ono Yakuhin Kogyo KK) published on 23 January 2002 discloses pyrazolopyridine compounds of the following
30 formula:



JP-2002-20386-A
(Ono)

- wherein R^1 denotes 1) a group $-\text{OR}^6$, 2) a group $-\text{SR}^7$, 3) a C2-8 alkynyl group, 4) a nitro group, 5) a cyano group, 6) a C1-8 alkyl group substituted by a hydroxy group or a C1-8 alkoxy group, 7) a phenyl group, 8) a group $-\text{C}(\text{O})\text{R}^8$, 9) a group $-\text{SO}_2\text{NR}^9\text{R}^{10}$, 10) a
35 group $-\text{NR}^{11}\text{SO}_2\text{R}^{12}$, 11) a group $-\text{NR}^{13}\text{C}(\text{O})\text{R}^{14}$ or 12) a group $-\text{CH}=\text{NR}^{15}$. R^6 and R^7

denote i) a hydrogen atom, ii) a C1-8 alkyl group, iii) a C1-8 alkyl group substituted by a C1-8 alkoxy group, iv) a trihalomethyl group, v) a C3-7 cycloalkyl group, vi) a C1-8 alkyl group substituted by a phenyl group or vii) a 3-15 membered mono-, di- or tricyclic hetero ring containing 1-4 nitrogen atoms, 1-3 oxygen atoms and/or 1-3 sulphur atoms.

5 R^2 denotes 1) a hydrogen atom or 2) a C1-8 alkoxy group. R^3 denotes 1) a hydrogen atom or 2) a C1-8 alkyl group. R^4 denotes 1) a hydrogen atom, 2) a C1-8 alkyl group, 3) a C3-7 cycloalkyl group, 4) a C1-8 alkyl group substituted by a C3-7 cycloalkyl group, 5) a phenyl group which may be substituted by 1-3 halogen atoms or 6) a 3-15 membered mono-, di- or tricyclic hetero ring containing 1-4 nitrogen atoms, 1-3 oxygen atoms
10 and/or 1-3 sulphur atoms. R^5 denotes 1) a hydrogen atom, 2) a C1-8 alkyl group, 3) a C3-7 cycloalkyl group, 4) a C1-8 alkyl group substituted by a C3-7 cycloalkyl group or 5) a phenyl group which may be substituted by 1-3 substituents. In group R^3 , a hydrogen atom is preferred. In group R^4 , methyl, ethyl, cyclopropyl, cyclobutyl or cyclopentyl are preferred. The compounds of JP-2002-20386-A are stated as having PDE4 inhibitory
15 activity and as being useful in the prevention and/or treatment of inflammatory diseases and many other diseases.

EP 0 076 035 A1 (ICI Americas) discloses pyrazolo[3,4-b]pyridine derivatives as central nervous system depressants useful as tranquilisers or ataractic agents for the relief of
20 anxiety and tension states.

The compound cartazolate is known (ethyl 1-ethyl-4-n-butylamino-1H-pyrazolo[3,4-b]-pyridine-5-carboxylate). J.W. Daly et al., *Med. Chem. Res.*, 1994, 4, 293-306 and D. Shi et al., *Drug Development Research*, 1997, 42, 41-56 disclose a series of
25 4-(amino)substituted 1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid derivatives and their affinities at A_1 - and A_{2A} -adenosine receptors, and the latter paper discloses their affinities at various binding sites of the $GABA_A$ -receptor channel. S. Schenone et al., *Bioorg. Med. Chem. Lett.*, 2001, 11, 2529-2531 disclose a series of 4-amino-1-(2-chloro-2-phenylethyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid ethyl esters as A_1 -
30 adenosine receptor ligands.


S.S.Chakravorti et al., *Indian J. Chem.*, 1978, 16B(2), 161-3 discloses the compounds 4-hydroxy-1,3-diphenyl-5-(3',4'-dihydroisoquinol-1'-yl)-pyrazolo[3,4-b]pyridine and 1,3-diphenyl-4-hydroxy-5-(3'-methyl-3',4'-dihydroisoquinol-1'-yl)-
35 pyrazolo[3,4-b]pyridine. These two compounds were tested for antifilarial activity but were found to have no significant microfilaricidal activity.

G. Sabitha et al., *Synthetic Commun.*, 1999, 29(4), 655-665 discloses a synthetic route to 5-substituted-6-amino-1-phenyl-3-(methyl or phenyl)-pyrazolo[3,4-b]pyridines wherein
40 the 5-substituent of the pyrazolo[3,4-b]pyridine is benzimidazol-2-yl, 5-chloro-benzoxazol-2-yl, or benzothiazol-2-yl. Though declared to be "biologically interesting molecules", there is however no disclosure that these compounds had been

tested in any pharmacological tests and there is no disclosure of any general or specific biological activity of these compounds.

- It is desirable to find new compounds which bind to, and preferably inhibit,
5 phosphodiesterase type IV (PDE4).

The present invention provides a compound of formula (I) or a salt thereof (in particular, a pharmaceutically acceptable salt thereof):




wherein:

R¹ = a hydrogen atom, C₁₋₄alkyl, C₁₋₃fluoroalkyl or -(CH₂)₂OH;

R² is a hydrogen atom, methyl or C₁fluoroalkyl;

R³ is optionally substituted C₁₋₈alkyl, optionally substituted C₃₋₈cycloalkyl, optionally substituted phenyl, or an optionally substituted heterocyclic group of sub-formula (aa), (bb) or (cc):



in which n¹ and n² are 1 or 2; and Y is O, S, SO₂, or NR⁴; where R⁴ is a hydrogen atom, C₁₋₂alkyl, C₁₋₂fluoroalkyl, C(O)NH₂, C(O)-C₁₋₂alkyl, or C(O)-C₁fluoroalkyl; provided that Y is not NR⁴ when the heterocyclic group is of sub-formula (aa);

wherein in R³ the C₁₋₈alkyl is optionally substituted with one or two substituents being oxo (=O), OH, C₁₋₂alkoxy or C₁₋₂fluoroalkoxy; and wherein any such substituent is not substituted at the R³ carbon atom attached to the -NH- group of formula (I);


- wherein in R³ the phenyl is optionally substituted with one substituent being fluoro, chloro, C₁₋₂alkyl, C₁₋₂fluoroalkyl, C₁₋₂alkoxy, C₁₋₂fluoroalkoxy or cyano;

wherein in R^3 the C_{3-8} cycloalkyl or the heterocyclic group of sub-formula (aa), (bb) or (cc) is optionally substituted with one or two substituents being oxo ($=O$), OH, C_{1-2} alkoxy, C_{1-2} fluoroalkoxy, or C_{1-2} alkyl; and wherein any OH, alkoxy or

- 5 fluoroalkoxy substituent is not substituted at the R^3 ring carbon attached to the -NH- group of formula (I) and is not substituted at either R^3 ring carbon bonded to the Y group of the heterocyclic group (aa), (bb) or (cc); and

and wherein Het is of sub-formula (i), (ii), (iii) or (iv):

10



wherein:

W^1 , W^2 and W^4 is N; and W^3 is NR^W ;

15

X^1 , X^3 and X^4 is N or CR^X ; and X^2 is O, S or NR^X ;

Y^1 , Y^2 and Y^3 is CR^Y or N; and Y^4 is O, S or NR^Y ;

20 Z^1 is O, S or NR^Z ; and Z^2 , Z^3 and Z^4 is N or CR^Z ;

wherein:

R^W is a hydrogen atom (H) or C_{1-2} alkyl;

25 R^X and R^Y independently are:

a hydrogen atom (H);

C_{1-8} alkyl;

C_{3-6} cycloalkyl;

$-(CH_2)_n^3-SO_2-R^5$ wherein n^3 is 1 or 2 and R^5 is C_{1-3} alkyl or $-NH-C_{1-2}$ alkyl;

30 $-(CH_2)_n^4-NR^6R^7$ wherein n^4 is 0, 1 or 2, and R^6 and R^7 independently are H,

C_{1-6} alkyl e.g. C_{1-4} alkyl, $-C(O)-C_{1-2}$ alkyl or $-SO_2-C_{1-2}$ alkyl; or R^6 and R^7 together are $-(CH_2)_n^5-X^5-(CH_2)_n^6-$ in which n^5 and n^6 independently are 2 or 3 and X^5 is a bond, $-CH_2-$, O, NR^8 wherein R^8 is H or C_{1-2} alkyl;

$-(CH_2)_n^7-O-R^9$ wherein n^7 is 1 or 2 and R^9 is H or C_{1-6} alkyl;

35 $-C(O)-NR^{10}R^{11}$ wherein R^{10} and R^{11} independently are H or C_{1-6} alkyl; or R^{10} and R^{11} together are $-(CH_2)_n^8-X^6-(CH_2)_n^9-$ in which n^8 and n^9

independently are 2 or 3 and X^6 is a bond, $-CH_2-$, O, NR^{12} wherein R^{12} is H or C_{1-2} alkyl;

$-C(O)-OR^{13}$ wherein R^{13} is H or C_{1-6} alkyl;

a 4-, 5-, 6- or 7-membered saturated heterocyclic ring containing one O ring atom or one NR^{14} ring group wherein R^{14} is H or C_{1-4} alkyl, said heterocyclic ring being optionally substituted (at a position or positions other than any NR^{14} position) by one oxo ($=O$) and/or one C_{1-4} alkyl substituent; or

$-(CH_2)_n^{10}-Ar$ wherein n^{10} is 0, 1 or 2 and

(i) Ar is phenyl optionally substituted by one or two substituents being fluoro, chloro, C_{1-2} alkyl, C_{1-2} fluoroalkyl, C_{1-2} alkoxy, C_{1-2} fluoroalkoxy or cyano;

or

(ii) Ar is an optionally substituted 5- or 6-membered heterocyclic aromatic ring containing 1, 2 or 3 heteroatoms selected from O, N or S; and wherein when the heterocyclic aromatic ring Ar contains 2 or 3 heteroatoms, one is selected from O, N and S and the remaining heteroatom(s) are N; and wherein the heterocyclic aromatic ring Ar is optionally substituted by one or two C_{1-4} alkyl groups; and

R^Z is a hydrogen atom (H) or C_{1-2} alkyl.

In compounds, for example in the compounds of formula (I), an "alkyl" group or moiety may be straight-chain or branched. Alkyl groups, for example C_{1-8} alkyl or C_{1-6} alkyl or C_{1-4} alkyl or C_{1-2} alkyl, which may be employed include C_{1-6} alkyl or C_{1-4} alkyl or C_{1-2} alkyl such as methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl and any branched isomers thereof such as isopropyl, t-butyl, sec-butyl, isobutyl, 3-methylbutan-2-yl, 2-ethylbutan-1-yl, and the like.

A corresponding meaning is intended for "alkoxy", "alkylene", and like terms derived from alkyl. For example, "alkoxy" such as C_{1-6} alkoxy or C_{1-4} alkoxy includes methoxy, ethoxy, propyloxy, and oxy derivatives of the alkyls listed above.

"Alkylsulfonyl" such as C_{1-4} alkylsulfonyl includes methylsulfonyl (methanesulfonyl), ethylsulfonyl, and others derived from the alkyls listed above. "Alkylsulfonyloxy" such as C_{1-4} alkylsulfonyloxy includes methanesulfonyloxy (methylsulfonyloxy), ethanesulfonyloxy, *et al.*

"Cycloalkyl", for example C_{3-8} cycloalkyl, includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and the like. Preferably, a C_{3-8} cycloalkyl group is C_{3-6} cycloalkyl or C_{5-6} cycloalkyl, that is the cycloalkyl group contains a 3-6 membered or 5-6 membered carbocyclic ring respectively.

"Fluoroalkyl" includes alkyl groups with one, two, three, four, five or more fluorine substituents, for example C_{1-4} fluoroalkyl or C_{1-2} fluoroalkyl such as

monofluoromethyl, difluoromethyl, trifluoromethyl, pentafluoroethyl, etc.

"Fluoroalkoxy" includes C_{1-4} fluoroalkoxy or C_{1-2} fluoroalkoxy such as

trifluoromethoxy, pentafluoroethoxy, monofluoromethoxy, difluoromethoxy, etc.
"Fluoroalkylsulfonyl" such as C₁₋₄fluoroalkylsulfonyl includes

trifluoromethanesulfonyl, pentafluoroethylsulfonyl, etc.

- 5 A halogen atom ("halo") present in compounds, for example in the compounds of formula (I), can be a fluorine, chlorine, bromine or iodine atom ("fluoro", "chloro", "bromo" or "iodo").

- 10 Preferably, R¹ is C₁₋₄alkyl, C₁₋₃fluoroalkyl or -(CH₂)₂OH; more preferably C₁₋₃alkyl, C₁₋₂fluoroalkyl or -(CH₂)₂OH; still more preferably C₂₋₃alkyl, C₂fluoroalkyl or -(CH₂)₂OH; and yet more preferably C₂alkyl or C₂fluoroalkyl. When R¹ is C₁₋₄alkyl or C₁₋₃fluoroalkyl, it can be straight-chained or branched. R¹ can for example be methyl, trifluoromethyl, ethyl, n-propyl, isopropyl, isobutyl, C₂fluoroalkyl or -(CH₂)₂OH; and more preferably R¹ is ethyl, n-propyl, C₂fluoroalkyl or -(CH₂)₂OH.
15 R¹ is most preferably ethyl.

Preferably, R² is a hydrogen atom (H).

- 20 Where R³ is optionally substituted phenyl, the optional substituent can be at the 2-, 3- or 4-position of the phenyl ring, e.g. at the 4-position. For example, R³ can be phenyl or fluorophenyl; in particular 4-fluorophenyl.

- R³ is preferably optionally substituted C₁₋₈alkyl, optionally substituted C₃₋₈cycloalkyl, or an optionally substituted heterocyclic group of sub-formula (aa), (bb) or (cc).
25 Preferably, in R³ there is one substituent or no substituent.

- Where R³ is optionally substituted C₁₋₈alkyl, it is preferably optionally substituted C₁₋₆alkyl or more preferably optionally substituted C₃₋₆alkyl. In these 3 cases, preferably R³ is unsubstituted alkyl such as n-propyl, isopropyl, isobutyl, sec-butyl, n-butyl, t-butyl, 3-methylbutan-2-yl, or 2-ethylbutan-1-yl. Where R³ is optionally substituted C₁₋₈alkyl, it is most preferably isobutyl, sec-butyl, t-butyl or 3-methylbutan-2-yl (for example (R)-3-methylbutan-2-yl or (S)-3-methylbutan-2-yl).
30

- In one optional embodiment, where R³ is optionally substituted C₃₋₈cycloalkyl, it is not optionally substituted C₅cycloalkyl, i.e. not optionally substituted cyclopentyl. In this case, more preferably, R³ is optionally substituted C₆₋₈cycloalkyl.
35

- Where R³ is optionally substituted C₃₋₈cycloalkyl, it is more preferably C₆cycloalkyl (i.e. cyclohexyl) optionally substituted with one or two substituents being oxo (=O), OH, C₁₋₂alkoxy, C₁₋₂fluoroalkoxy, or C₁₋₂alkyl, and wherein any OH, alkoxy or
40

fluoroalkoxy substituent is not substituted at the R^3 ring carbon attached to the -NH- group of formula (I).

5 Where R^3 is optionally substituted C_{3-8} cycloalkyl, the optional substituent preferably comprises (e.g. is) OH or oxo. Optionally, in R^3 , the C_{3-8} cycloalkyl is unsubstituted.

10 Where R^3 is optionally substituted C_{3-8} cycloalkyl, e.g. optionally substituted C_{5-8} cycloalkyl such as optionally substituted C_6 cycloalkyl (cyclohexyl), the one or two optional substituents if present optionally comprises (e.g. is) a substituent at the 3-, 4- or 5- position of the R^3 cycloalkyl ring. Any OH substituent is more preferably at the 3- or 5-position of the R^3 cycloalkyl ring. (In this connection, the 1-position of the R^3 cycloalkyl ring is deemed to be the connection point to the -NH- in formula (I)).

15 Where R^3 is optionally substituted C_{3-8} cyclohexyl, R^3 is still more preferably cyclohexyl (i.e. unsubstituted) or cyclohexyl substituted by one oxo (=O), OH, C_{1-2} alkoxy or C_{1-2} fluoroalkoxy substituent. The optional substituent is preferably at the 3- or 4- position of the R^3 cyclohexyl ring; more preferably any OH substituent is preferably at the 3-position of the R^3 cyclohexyl ring.

20 Where R^3 is optionally substituted C_{3-8} cycloalkyl, R^3 can for example be 4-hydroxy-cyclohexyl, but R^3 is most preferably cyclohexyl (i.e. unsubstituted) or 3-hydroxy-cyclohexyl or 4-oxo-cyclohexyl.


25 Where R^3 is optionally substituted C_5 cycloalkyl (cyclopentyl), R^3 can for example be cyclopentyl (i.e. unsubstituted) or 3-hydroxy-cyclopentyl.

30 Where R^3 is the heterocyclic group of sub-formula (aa), (bb) or (cc), then preferably Y is O, S, SO_2 or N-C(O)-Me, more preferably O or N-C(O)-Me. (In the last case, R^4 is -C(O)-Me). This is provided that R^3 is not N-C(O)-Me when the heterocyclic group is of sub-formula (aa).


35 In R^3 , suitably the heterocyclic group is of sub-formula (bb). In sub-formula (bb), n^1 is preferably 1. In sub-formula (cc), n^2 is preferably 1. That is, six-membered rings are preferred in the R^3 heterocyclic group.

Preferably, in R^3 , the heterocyclic group of sub-formula (aa), (bb) or (cc) is unsubstituted. In the R^3 heterocyclic group of sub-formula (aa), (bb) or (cc), the optional substituent preferably comprises (e.g. is) OH or oxo.


Preferably, NHR^3 is of sub-formula (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), (L), (m), (n), (o), (p), (q), (r), (s) or (t):




(a)




(b)




(c)




(d)




(e)




(f)




(g)




(h)




(i)




(j)




(k)




(L)




(m)




(n)




(o)




(p)




(q)



(r)



(s)



(t)

- 5 In the sub-formulae (a) to (t) etc above, the -NH- connection point of the NHR^3 group to the 4-position of the pyrazolopyridine of formula (I) is underlined.

Preferably, NHR^3 is of sub-formula (c), (d), (e), (f), (h), (i), (j), (k), (m), (n), (o), (p), (q), (r), (s) or (t). More preferably NHR^3 is of sub-formula (c), (h), (k), (n), (o), (r), (s) or (t).

Most preferably, R^3 is tetrahydro-2H-pyran-4-yl; that is NHR^3 is most preferably of sub-formula (h), shown above.

Preferably, Het is of sub-formula (i) or (iii); more preferably Het is of sub-formula (i).

5


X^1 , X^3 and/or X^4 is often N (a nitrogen atom).

Y^1 , Y^2 and/or Y^3 is often CR^Y .


10 Suitably, Z^1 is O or S.

Preferably, Het is of sub-formula (ia), (ib), (ic), (id), (ie), or (if); more preferably of sub-formula (ia), (ib), (ic), (id), or (ie); still more preferably of sub-formula (ia), (ib), (ic), or (id); yet more preferably preferably of sub-formula (ia) or (ib).


15




(ia)




(ib)




(ic)



(id)



(ie)



(if)

For the Het group in general, R^W and/or R^Z independently is/are suitably a hydrogen atom (H).

20

For the Het group in general, preferably, one of R^X and R^Y is as defined herein and the other of R^X and R^Y is a hydrogen atom (H) or C_{1-2} alkyl. More preferably, one of R^X and R^Y is as defined herein and the other of R^X and R^Y is a hydrogen atom (H).

25 Preferably, one of R^X and R^Y is: C_{1-8} alkyl; C_{3-6} cycloalkyl; $-(CH_2)_n^3-SO_2-R^5$; $-(CH_2)_n^4-NR^6R^7$; $-(CH_2)_n^7-O-R^9$; $-C(O)-NR^{10}R^{11}$; $-C(O)-OR^{13}$; or the 4-, 5-, 6- or 7-membered optionally substituted saturated heterocyclic ring. More preferably, one of R^X and R^Y is: C_{1-8} alkyl; $-(CH_2)_n^3-SO_2-R^5$; or the 4-, 5-, 6- or 7-membered optionally


substituted saturated heterocyclic ring. In these cases, as mentioned above, it is preferred that the other of R^X and R^Y is a hydrogen atom (H) or C_{1-2} alkyl.


When R^X and/or R^Y is C_{1-8} alkyl, preferably it is C_{1-6} alkyl, e.g. C_{3-6} alkyl and/or C_{1-4} alkyl such as methyl, isopropyl, isobutyl or t-butyl.

When R^X and/or R^Y is C_{3-6} cycloalkyl, it can be for example cyclopropyl.

When R^X and/or R^Y is $-(CH_2)_n^3-SO_2-R^5$, then preferably n^3 is 1 and/or R^5 is preferably C_{1-3} alkyl or C_{1-2} alkyl such as methyl. Most preferably, $-(CH_2)_n^3-SO_2-R^5$ is $-CH_2SO_2Me$.


When R^X and/or R^Y is $-(CH_2)_n^4-NR^6R^7$, then preferably n^4 is 0 or 1. R^6 is preferably H or C_{1-6} alkyl. R^7 is preferably C_{1-6} alkyl. Where R^6 and/or R^7 is C_{1-6} alkyl, then it is preferably C_{1-4} alkyl e.g. methyl. In an alternative preferable embodiment, R^6 and R^7 together are $-(CH_2)_n^5-X^5-(CH_2)_n^6-$, in which case it is preferable that n^5 is 2 and/or n^6 is 2. For example, $-(CH_2)_n^4-NR^6R^7$ can be NMe_2 ($n^4 = 0$; $R^6 = R^7 = Me$), or

$-CH_2NMe_2$ ($n^4 = 1$; $R^6 = R^7 = Me$), or  ($n^4 = 1$; R^6 and R^7 together are

$-(CH_2)_2-N(Me)-(CH_2)_2-$) or  ($n^4 = 1$; R^6 and R^7 together are $-(CH_2)_2-O-(CH_2)_2-$).

When R^X and/or R^Y is $-(CH_2)_n^7-O-R^9$, then n^7 is preferably 1 and/or R^9 is preferably C_{1-4} alkyl such as methyl or t-butyl. For example, $-(CH_2)_n^7-O-R^9$ can be $-CH_2-O-tBu$ or $-CH_2-O-Me$.

When R^X and/or R^Y is $-C(O)-NR^{10}R^{11}$, then preferably R^{10} is H and/or preferably R^{11} is C_{1-6} alkyl e.g. C_{1-4} alkyl such as isopropyl. For example, $-C(O)-NR^{10}R^{11}$ can be





. In an alternative embodiment, when R^{10} and R^{11} together are $-(CH_2)_n^8-X^6-(CH_2)_n^9-$, then preferably n^8 is 2 and/or n^9 is 2.

When R^X and/or R^Y is $-C(O)-OR^{13}$, and when R^{13} is C_{1-6} alkyl, then R^{13} is preferably C_{1-4} alkyl such as methyl (i.e. R^Y is $-CO_2Me$) or ethyl.

When R^X and/or R^Y is the 4-, 5-, 6- or 7-membered optionally substituted saturated heterocyclic ring containing one O ring atom or one NR^{14} ring group, then suitably the optionally substituted saturated heterocyclic ring is 4-, 5- or 6-membered. When R^{14} and/or a or the optional ring substituent is C_{1-4} alkyl, it is suitably C_{1-2} alkyl such as methyl. When the saturated heterocyclic ring is optionally substituted (at a position other than any NR^{14} position) by C_{1-4} alkyl, then preferably the optional C_{1-4} alkyl is substituted at the carbon atom directly attached to the 5-membered ring in sub-formula-

(i), (ii), (iii) or (iv) of Het. For example, the 4-, 5-, 6- or 7-membered optionally substituted saturated heterocyclic ring can be tetrahydro-2H-pyran-4-yl, or



When R^X and/or R^Y is $-(CH_2)_n$ -Ar then preferably n^{10} is 0 or 1. When Ar is the optionally substituted 5- or 6-membered heterocyclic aromatic ring containing 1, 2 or 3 heteroatoms selected from O, N or S, then Ar can be optionally substituted furyl, thienyl, pyrrolyl, 1,3-oxazolyl, 1,3-thiazolyl, imidazolyl, oxadiazolyl (e.g. 1,3,4- or 1,2,4-oxadiazolyl), thiadiazolyl (e.g. 1,3,4- or 1,2,4-), pyridyl, triazolyl (e.g. 1,2,4-triazolyl), triazinyl, pyridazyl, pyrimidinyl, pyrazolyl, isothiazolyl (1,2-thiazolyl), or isoxazolyl (1,2-oxazolyl). When Ar is the optionally substituted 5- or 6-membered heterocyclic aromatic ring, the ring is preferably optionally substituted by one or two C_{1-2} alkyl groups; more preferably there is/are one or no substituents.

It is most preferred that the compound of formula (I) or the salt thereof is:

- 25 N-Cyclopentyl-1-ethyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine,
N-Cyclopentyl-1-ethyl-5-{5-[(methylsulfonyl)methyl]-1,3,4-oxadiazol-2-yl}-1H-pyrazolo[3,4-b]pyridin-4-amine,
N-Cyclopentyl-1-ethyl-5-(5-isopropyl-1,3,4-oxadiazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine,
N-Cyclopentyl-1-ethyl-5-(5-methyl-1,3,4-thiadiazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine,
- 30 N-Cyclopentyl-1-ethyl-5-{5-[(methylsulfonyl)methyl]-1,3,4-thiadiazol-2-yl}-1H-pyrazolo[3,4-b]pyridin-4-amine,
N-Cyclopentyl-1-ethyl-5-(5-isopropyl-1,3,4-thiadiazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine,
1-Ethyl-N-(4-fluorophenyl)-5-(3-methyl-1,2,4-oxadiazol-5-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine,
- 35 N-Cyclopentyl-5-(1,3-dimethyl-1H-1,2,4-triazol-5-yl)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-4-amine,
1-Ethyl-5-(5-isopropyl-1,3,4-oxadiazol-2-yl)-N-tetrahydro-2H-pyran-4-yl-1H-pyrazolo[3,4-b]pyridin-4-amine,
N-Cyclohexyl-1-ethyl-5-(5-isopropyl-1,3,4-oxadiazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine,

- 1-Ethyl-N-isobutyl-5-(5-isopropyl-1,3,4-oxadiazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine,
1-Ethyl-N-isobutyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine,
N-Cyclohexyl-1-ethyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine,
1-Ethyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)-N-tetrahydro-2H-pyran-4-yl-1H-pyrazolo[3,4-
5 b]pyridin-4-amine,
N-[(1R)-1,2-dimethylpropyl]-1-ethyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)-1H-pyrazolo[3,4-
b]pyridin-4-amine,
N-[(1S)-1,2-dimethylpropyl]-1-ethyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)-1H-pyrazolo[3,4-
b]pyridin-4-amine,
10 5-(5-Tert-butyl-1,3,4-oxadiazol-2-yl)-1-ethyl-N-tetrahydro-2H-pyran-4-yl-1H-pyrazolo[3,4-
b]pyridin-4-amine,
5-(5-Tert-butyl-1,3,4-oxadiazol-2-yl)-N-cyclohexyl-1-ethyl-1H-pyrazolo[3,4-b]pyridin-4-amine,
5-(5-Tert-butyl-1,3,4-oxadiazol-2-yl)-N-cyclopentyl-1-ethyl-1H-pyrazolo[3,4-b]pyridin-4-amine,
5-(5-Tert-butyl-1,3,4-oxadiazol-2-yl)-1-ethyl-N-isobutyl-1H-pyrazolo[3,4-b]pyridin-4-amine,
15 5-(5-Tert-butyl-1,3,4-oxadiazol-2-yl)-N-[(1S)-1,2-dimethylpropyl]-1-ethyl-1H-pyrazolo[3,4-
b]pyridin-4-amine,
5-(5-Tert-butyl-1,3,4-oxadiazol-2-yl)-N-[(1R)-1,2-dimethylpropyl]-1-ethyl-1H-pyrazolo[3,4-
b]pyridin-4-amine,
1-Ethyl-5-{5-[(methylsulfonyl)methyl]-1,3,4-oxadiazol-2-yl}-N-tetrahydro-2H-pyran-4-yl-1H-
20 pyrazolo[3,4-b]pyridin-4-amine,
N-Cyclohexyl-1-ethyl-5-{5-[(methylsulfonyl)methyl]-1,3,4-oxadiazol-2-yl}-1H-pyrazolo[3,4-
b]pyridin-4-amine,
1-Ethyl-N-isobutyl-5-{5-[(methylsulfonyl)methyl]-1,3,4-oxadiazol-2-yl}-1H-pyrazolo[3,4-
b]pyridin-4-amine,
25 N-[(1S)-1,2-dimethylpropyl]-1-ethyl-5-{5-[(methylsulfonyl)methyl]-1,3,4-oxadiazol-2-yl}-1H-
pyrazolo[3,4-b]pyridin-4-amine,
N-[(1R)-1,2-dimethylpropyl]-1-ethyl-5-{5-[(methylsulfonyl)methyl]-1,3,4-oxadiazol-2-yl}-1H-
pyrazolo[3,4-b]pyridin-4-amine,
1-Ethyl-5-(3-methyl-1,2,4-oxadiazol-5-yl)-N-tetrahydro-2H-pyran-4-yl-1H-pyrazolo[3,4-
30 b]pyridin-4-amine,
1-Ethyl-5-[3-(methoxymethyl)-1,2,4-oxadiazol-5-yl]-N-tetrahydro-2H-pyran-4-yl-1H-
pyrazolo[3,4-b]pyridin-4-amine,
5-{3-[(Dimethylamino)methyl]-1,2,4-oxadiazol-5-yl}-1-ethyl-N-tetrahydro-2H-pyran-4-yl-1H-
pyrazolo[3,4-b]pyridin-4-amine,
35 1-Ethyl-5-[3-(morpholin-4-ylmethyl)-1,2,4-oxadiazol-5-yl]-N-tetrahydro-2H-pyran-4-yl-1H-
pyrazolo[3,4-b]pyridin-4-amine,
5-(5-Cyclopropyl-1,3,4-oxadiazol-2-yl)-1-ethyl-N-tetrahydro-2H-pyran-4-yl-1H-pyrazolo[3,4-
b]pyridin-4-amine,
N-(1-Acetylpiperidin-4-yl)-1-ethyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-
40 4-amine,
1-Ethyl-5-[5-(3-methyloxetan-3-yl)-1,3,4-oxadiazol-2-yl]-N-tetrahydro-2H-pyran-4-yl-1H-
pyrazolo[3,4-b]pyridin-4-amine,

- 1-Ethyl-5-{5-[(4-methylpiperazin-1-yl)methyl]-1,3,4-oxadiazol-2-yl}-N-tetrahydro-2H-pyran-4-yl-1H-pyrazolo[3,4-b]pyridin-4-amine,
 5-[1-Ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]-N-isopropyl-1,3,4-oxadiazole-2-carboxamide,
 5 4-{5-[1-Ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}-1-methylpyrrolidin-2-one,
 1-Ethyl-N-tetrahydro-2H-pyran-4-yl-5-(5-tetrahydro-2H-pyran-4-yl-1,3,4-oxadiazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine,
 1-Ethyl-5-[5-(morpholin-4-ylmethyl)-1,3,4-oxadiazol-2-yl]-N-tetrahydro-2H-pyran-4-yl-1H-pyrazolo[3,4-b]pyridin-4-amine,
 10 5-[5-(Tert-butoxymethyl)-1,3,4-oxadiazol-2-yl]-1-ethyl-N-tetrahydro-2H-pyran-4-yl-1H-pyrazolo[3,4-b]pyridin-4-amine, or
 methyl 2-[1-ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,3-oxazole-4-carboxylate;
 15 or a salt thereof, e.g. a pharmaceutically acceptable salt thereof.

Because of their potential use in medicine, the salts of the compounds of formula (I) are preferably pharmaceutically acceptable. Suitable pharmaceutically acceptable salts can include acid or base addition salts. A pharmaceutically acceptable acid addition salt can be formed by reaction of a compound of formula (I) with a suitable inorganic or organic acid (such as hydrobromic, hydrochloric, sulfuric, nitric, phosphoric, succinic, maleic, acetic, fumaric, citric, tartaric, benzoic, p-toluenesulfonic, methanesulfonic or naphthalenesulfonic acid), optionally in a suitable solvent such as an organic solvent, to give the salt which is usually isolated for example by crystallisation and filtration. A pharmaceutically acceptable acid addition salt of a compound of formula (I) can be for example a hydrobromide, hydrochloride, sulfate, nitrate, phosphate, succinate, maleate, acetate, fumarate, citrate, tartrate, benzoate, p-toluenesulfonate, methanesulfonate or naphthalenesulfonate salt. A pharmaceutically acceptable base addition salt can be formed by reaction of a compound of formula (I) with a suitable inorganic or organic base, optionally in a suitable solvent such as an organic solvent, to give the base addition salt which is usually isolated for example by crystallisation and filtration. Other non-pharmaceutically acceptable salts, eg. oxalates, may be used, for example in the isolation of compounds of the invention, and are included within the scope of this invention. The invention includes within its scope all possible stoichiometric and non-stoichiometric forms of the salts of the compounds of formula (I).

Also included within the scope of the invention are all solvates, hydrates and complexes of compounds and salts of the invention.

Certain groups, substituents, compounds or salts included in the present invention may be present as isomers. The present invention includes within its scope all such isomers, including racemates, enantiomers and mixtures thereof.

Certain of the groups, e.g. heteroaromatic ring systems, included in compounds of formula (I) or their salts may exist in one or more tautomeric forms. The present invention includes within its scope all such tautomeric forms, including mixtures.


Especially when intended for oral medicinal use, the compound of formula (I) can optionally have a molecular weight of 1000 or less, for example 800 or less, in particular 650 or less or 600 or less. Molecular weight here refers to that of the unsolvated "free base" compound, that is excluding any molecular weight contributed by any addition salts, solvent (e.g. water) molecules, etc.

Synthetic Process Routes


The following processes can be used to make the compounds of formula (I):

Process A


Compounds of Formula I can be prepared by the cyclisation reaction of a compound of Formula II, for example with phosphorous oxychloride, in a suitable solvent such as acetonitrile. The reaction may require heating:



Compounds of Formula II may themselves be prepared by reacting a compound of Formula III with a suitably substituted hydrazine derivative of formula $R^YCONHNH_2$, under standard coupling conditions. For example a coupling reagent such as 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) may be used e.g. in the presence of hydroxybenzotriazole (HOBt), for example in a suitable solvent such as DMF:




Where the required hydrazine derivative $R^Y\text{CONHNH}_2$ is not readily available, compounds of Formula II may alternatively be prepared by initially reacting a compound of Formula III with t-butylcarbazate under standard coupling conditions. For example a coupling reagent such as EDC may be used, e.g. in the presence of hydroxybenzotriazole, for example in a suitable solvent such as DMF:




Subsequent Boc-deprotection of the resultant acid hydrazide derivative (Formula IV) to afford a hydrazide derivative of Formula V, can be achieved using a dilute acid such as 2M hydrochloric acid in an organic solvent such as dioxane. Conversion to the desired hydrazide derivative of Formula II can be achieved by reaction with an acid of formula $R^Y\text{CO}_2\text{H}$ under standard coupling conditions. For example a coupling agent such as EDC may be used e.g. in the presence of hydroxybenzotriazole, for example in a suitable solvent such as DMF. Alternatively, an activated acid derivative of formula $R^Y\text{CO-X}^{10}$ where X is a leaving group such as chloro (acid chloride) or $-\text{O-CO-R}^{30}$ or $-\text{O-SO}_2\text{-R}^{30}$ (where R^{30} can e.g. be R^Y or alkyl or aryl such as methyl, t-butyl or p-methylphenyl) may be used to effect formation of a hydrazide of Formula II, through reaction with a hydrazide derivative of Formula V.


Compounds of Formula III can be prepared by hydrolysis of an ester of Formula VI (for example $R^e = \text{Et}$), for example according to the method described by Yu et. al. in *J. Med Chem.*, 2001, 44, 1025-1027. This hydrolysis procedure usually involves reaction with a base such as sodium hydroxide or potassium hydroxide in a solvent such as ethanol or dioxane, one or both solvents preferably containing some water:




- Compounds of Formula VI can be prepared, e.g. according to the method described by Yu et. al. in *J. Med Chem.*, 2001, 44, 1025-1027, by reaction of a compound of Formula VII with an amine of Formula R^3NH_2 . The reaction is best carried out in the presence of a base such as triethylamine or diisopropylethyl amine in a solvent such as ethanol or dioxane and may require heating:




- Compounds of Formula VII are also described in the above reference and can be prepared first by reaction of a compound of Formula VIII with, for example, diethylethoxymethylene malonate (to afford $R^e = \text{Et}$) e.g. with heating, followed by reaction with phosphorous oxychloride, again with heating:



- Where the desired amino pyrazole of Formula VIII is not commercially available, preparation can be achieved, for example using methods described by Dorgan et. al. in *J. Chem. Soc., Perkin Trans.* 1980, 1 (4), 938-42, involving reaction of cyanoethyl hydrazine with a suitable aldehyde $R^{1a}CHO$ in a solvent such as ethanol, with heating, followed by reduction with, for example sodium in a solvent such as t-butanol. R^{1a} should be chosen so as to contain one less carbon atom than R^1 , for example $R^{1a} = \text{methyl}$ will afford $R^1 = \text{ethyl}$.


**Process B**

- 5 Compounds of Formula I can alternatively be prepared by reaction of a compound of Formula IX with an amine of formula R^3NH_2 , preferably in a solvent such as ethanol or acetonitrile, in the presence of a base such as DIPEA. Heating may be required to effect the conversion:



10


Compounds of Formula IX can themselves be prepared by reaction of a compound of Formula X with phosphorous oxychloride in a suitable solvent such as acetonitrile. The reaction may require heating:




15

- Compounds of Formula X can be prepared by initial reaction of an acid of Formula XI with standard amide coupling reagents such as EDC/HOBT or with thionyl chloride, followed by reaction of the thus formed activated intermediate with an acid hydrazide of Formula $\text{R}^Y\text{CONHNH}_2$:

20



Acids of Formula XI can themselves be prepared by hydrolysis of an ester of Formula VII using a base such as potassium hydroxide in a solvent such as aqueous dioxane.




5

Process C

Compounds of Formula XII can be prepared by reaction of a compound of Formula II with a reagent capable of inserting sulfur such as Lawesson's reagent, usually in a suitable solvent such as acetonitrile. The reaction may require heating:


10



Process D

15

Compounds of Formula XIII can be prepared by reaction of a compound of Formula VI ($R^e = Et$) with an amidoxime of formula $R^X C(NOH)NH_2$ and sodium ethoxide in the presence of molecular sieves and in a suitable solvent such as ethanol.




20


Process E

Compounds of Formula XIV can be prepared by reaction of a compound of Formula XV with a suitable acetimidate such as methyl acetimidate ($R^X = Me$) and triethylamine in a suitable solvent such as ethanol:

25



- 5 Compounds of Formula XV may themselves be prepared by reaction of a compound of Formula III with a suitably substituted hydrazine derivative of Formula $R^Z\text{NHNH}_2$, under standard coupling conditions. For example a coupling agent such as EDC may be used in the presence of hydroxybenzotriazole, in a suitable solvent such as DMF:



Process F

- 10 To make a compound of formula (I) wherein Het is optionally substituted 1,3-oxazol-2-yl, methods known to the skilled person can be used. For example, the 5-carboxylic acid of Formula (III) can be converted to a 5-(optionally-substituted 1,3-oxazol-2-yl)-pyrazolopyridine by the method shown in Example 41 or a modification of this method or by an analogous method.

- 20 The present invention therefore also provides a method of preparing a compound of formula (I) or a salt thereof, comprising :

- (a) cyclisation of a compound of formula (II) to an optionally substituted 1,3,4-oxadiazol-2-yl derivative at the 5-position of the pyrazolopyridine ring system, for example in the presence of phosphorus oxychloride, or
- 25 (b) reaction of a compound of formula (IX) with an amine of formula $R^3\text{NH}_2$, or
- (c) cyclisation of a compound of formula (II) to an optionally substituted 1,3,4-thiadiazol-2-yl derivative at the 5-position of the pyrazolopyridine ring system, for example in the presence of an agent capable of introducing sulfur such as Lawesson's reagent, or
- 30

(d) reaction of a compound of formula (VI), with an amidoxime of formula $R^X C(NO_2)NH_2$ or a salt thereof; or

- 5 (e) reaction of a compound of formula (XV) to an optionally substituted 1,2,4-triazol-3-yl or 5-yl derivative at the 5-position of the pyrazolopyridine ring system

and optionally converting the compound of formula (I) into a salt e.g. a pharmaceutically acceptable salt.

- 10 Salt formation processes may optionally be as described elsewhere herein.

Medical uses

- 15 The present invention also provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for use as an active therapeutic substance in a mammal such as a human. The compound or salt can be for use in the treatment and/or prophylaxis of any of the conditions described herein and/or for use as a phosphodiesterase inhibitor e.g. for use as a phosphodiesterase 4 (PDE4) inhibitor. "Therapy" may include treatment and/or prophylaxis.

- 20 Also provided is the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament (e.g. pharmaceutical composition) for the treatment and/or prophylaxis of an inflammatory and/or allergic disease in a mammal such as a human.

- 25 Also provided is a method of treatment and/or prophylaxis of an inflammatory and/or allergic disease in a mammal (e.g. human) in need thereof, which comprises administering to the mammal (e.g. human) a therapeutically effective amount of a compound of formula (I) as herein defined or a pharmaceutically acceptable salt thereof.

- 30 Phosphodiesterase 4 inhibitors are thought to be useful in the treatment and/or prophylaxis of a variety of diseases, especially inflammatory and/or allergic diseases, in mammals such as humans, for example: asthma, chronic bronchitis, emphysema, atopic dermatitis, urticaria, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis,
35 eosinophilic granuloma, psoriasis, rheumatoid arthritis, septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and brain, chronic glomerulonephritis, endotoxic shock, adult respiratory distress syndrome, or multiple sclerosis.

- 40 In the treatment and/or prophylaxis, the inflammatory and/or allergic disease is preferably chronic obstructive pulmonary disease (COPD), asthma, or allergic rhinitis in a mammal

(e.g. human). More preferably, the treatment and/or prophylaxis is of COPD or asthma in a mammal (e.g. human). PDE4 inhibitors are thought to be effective in the treatment of asthma (e.g. see M.A.Giembycz, *Drugs*, Feb. 2000, 59(2), 193-212; Z. Huang et al., *Current Opinion in Chemical Biology*, 2001, 5: 432-438; and refs cited therein) and
5 COPD (e.g. see S.L. Wolda, *Emerging Drugs*, 2000, 5(3), 309-319; Z. Huang et al., *Current Opinion in Chemical Biology*, 2001, 5: 432-438; and refs cited therein). COPD is often characterised by the presence of airflow obstruction due to chronic bronchitis and/or emphysema (SL Wolda, 2000).

10 **Pharmaceutical compositions and dosing**

For use in medicine, the compounds of the present invention are usually administered as a pharmaceutical composition.

15 The present invention therefore provides in a further aspect a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers and/or excipients.

The pharmaceutical composition can be for use in the treatment and/or prophylaxis of any of the conditions described herein.

20 The compounds of formula (I) and/or the pharmaceutical composition may be administered, for example, by oral, parenteral (e.g. intravenous, subcutaneous, or intramuscular), inhaled or nasal administration. Accordingly, the pharmaceutical composition is preferably suitable for oral, parenteral (e.g. intravenous, subcutaneous, or intramuscular), inhaled or nasal administration. More preferably, the pharmaceutical composition is suitable for inhaled or oral administration, e.g. to a mammal such as a
25 human. Inhaled administration involves topical administration to the lung e.g. by aerosol or dry powder composition. Oral administration to a human is most preferred.

A pharmaceutical composition suitable for oral administration can be liquid or solid; for example it can be a syrup, suspension or emulsion, a tablet, a capsule or a lozenge.

30 A liquid formulation will generally consist of a suspension or solution of the compound or pharmaceutically acceptable salt in a suitable pharmaceutically acceptable liquid carrier(s), for example an aqueous solvent such as water, ethanol or glycerine, or a non-aqueous solvent, such as polyethylene glycol or an oil. The formulation may also contain a suspending agent, preservative, flavouring and/or colouring agent.

35 A pharmaceutical composition suitable for oral administration being a tablet can comprise one or more pharmaceutically acceptable carriers and/or excipients suitable for preparing tablet formulations. Examples of such carriers include lactose and cellulose. The tablet can also or instead contain one or more pharmaceutically acceptable excipients, for example binding agents, lubricants such as magnesium stearate, and/or
40 tablet disintegrants.

A pharmaceutical composition suitable for oral administration being a capsule can be prepared using encapsulation procedures. For example, pellets containing the active ingredient can be prepared using a suitable pharmaceutically acceptable carrier and then

filled into a hard gelatin capsule. Alternatively, a dispersion or suspension can be prepared using any suitable pharmaceutically acceptable carrier, for example an aqueous gum or an oil and the dispersion or suspension then filled into a soft gelatin capsule.

5 A parenteral composition can comprise a solution or suspension of the compound or pharmaceutically acceptable salt in a sterile aqueous carrier or parenterally acceptable oil. Alternatively, the solution can be lyophilised; the lyophilised parenteral pharmaceutical composition can be reconstituted with a suitable solvent just prior to administration.

10 Compositions for nasal or inhaled administration may conveniently be formulated as aerosols, drops, gels or dry powders.

Aerosol formulations, e.g. for inhaled administration, can comprise a solution or fine suspension of the active substance in a pharmaceutically acceptable aqueous or non-aqueous solvent. Aerosol formulations can be presented in single or multidose quantities in sterile form in a sealed container, which can take the form of a cartridge or refill for 15 use with an atomising device or inhaler. Alternatively the sealed container may be a unitary dispensing device such as a single dose nasal inhaler or an aerosol dispenser fitted with a metering valve (metered dose inhaler) which is intended for disposal once the contents of the container have been exhausted.

20 Where the dosage form comprises an aerosol dispenser, it preferably contains a suitable propellant under pressure such as compressed air, carbon dioxide, or an organic propellant such as a chlorofluorocarbon (CFC) or hydrofluorocarbon (HFC). Suitable CFC propellants include dichlorodifluoromethane, trichlorofluoromethane and dichlorotetrafluoroethane. Suitable HFC propellants include 1,1,1,2,3,3,3- 25 heptafluoropropane and 1,1,1,2-tetrafluoroethane. The aerosol dosage forms can also take the form of a pump-atomiser.

Optionally, in particular for dry powder inhalable compositions, a pharmaceutical composition for inhaled administration can be incorporated into a plurality of sealed dose containers (e.g. containing the dry powder composition) mounted longitudinally in a strip or ribbon inside a suitable inhalation device. The container is rupturable or peel-openable 30 on demand and the dose of e.g. the dry powder composition can be administered by inhalation via the device such as the DISKUS TM device, marketed by GlaxoSmithKline. The DISKUS TM inhalation device is for example described in GB 2,242,134 A, and in such device at least one container for the pharmaceutical composition in powder form (the at least one container preferably being a plurality of sealed dose containers mounted 35 longitudinally in a strip or ribbon) is defined between two members peelably secured to one another; the device comprises: means defining an opening station for the said at least one container; means for peeling the members apart at the opening station to open the container; and an outlet, communicating with the opened container, through which a user can inhale the pharmaceutical composition in powder form from the opened container.

40 Preferably the composition is in unit dose form such as a tablet or capsule for oral administration.

In the pharmaceutical composition, each dosage unit for oral or parenteral administration preferably contains from 0.01 to 3000 mg, more preferably 0.5 to 1000

mg, of a compound of the formula (I) or a pharmaceutically acceptable salt thereof, calculated as the free base. Each dosage unit for nasal or inhaled administration preferably contains from 0.001 to 50 mg, more preferably 0.01 to 5 mg, of a compound of the formula (I) or a pharmaceutically acceptable salt thereof, calculated as the free base.

The pharmaceutically acceptable compounds or salts of the invention can be administered in a daily dose (for an adult patient) of, for example, an oral or parenteral dose of 0.01 mg to 3000 mg per day or 0.5 to 1000 mg per day, or a nasal or inhaled dose of 0.001 to 50 mg per day or 0.01 to 5 mg per day, of the compound of the formula (I) or a pharmaceutically acceptable salt thereof, calculated as the free base.

Combinations


The compounds, salts and/or pharmaceutical compositions according to the invention may also be used in combination with another therapeutically active agent, for example, a β_2 adrenoreceptor agonist, an anti-histamine, an anti-allergic or an anti-inflammatory agent.

The invention thus provides, in a further aspect, a combination comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof together with another therapeutically active agent, for example, a β_2 -adrenoreceptor agonist, an anti-histamine, an anti-allergic, an anti-inflammatory agent or an antiinfective agent.

Examples of β_2 -adrenoreceptor agonists include salmeterol (eg as racemate or a single enantiomer such as the R-enantiomer), salbutamol, formoterol, salmefamol, fenoterol or terbutaline and salts thereof, for example the xinafoate salt of salmeterol, the sulphate salt or free base of salbutamol or the fumarate salt of formoterol. Long-acting β_2 -adrenoreceptor agonists are preferred, especially those having a therapeutic effect over a 24 hour period such as salmeterol or formoterol.

Preferred long acting β_2 -adrenoreceptor agonists include those described in WO 02/66422A.

Especially preferred long-acting β_2 -adrenoreceptor agonists include compounds of formula(X):



or a salt or solvate thereof, wherein in formula (X):

m is an integer of from 2 to 8;

n is an integer of from 3 to 11,

with the proviso that $m + n$ is 5 to 19,

R^{11} is $-XSO_2NR^{16}R^{17}$ wherein X is $-(CH_2)_p-$ or C_{2-6} alkenylene;

R^{16} and R^{17} are independently selected from hydrogen, C_{1-6} alkyl, C_{3-7} cycloalkyl, $C(O)NR^{18}R^{19}$, phenyl, and phenyl (C_{1-4} alkyl)-,

5 or R^{16} and R^{17} , together with the nitrogen to which they are bonded, form a 5-, 6-, or 7-membered nitrogen containing ring, and R^{16} and R^{17} are each optionally substituted by one or two groups selected from halo, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, hydroxy-substituted C_{1-6} alkoxy, $-CO_2R^{18}$, $-SO_2NR^{18}R^{19}$, $-CONR^{18}R^{19}$, $-NR^{18}C(O)R^{19}$, or a 5-, 6- or 7-membered heterocyclic ring;

10 R^{18} and R^{19} are independently selected from hydrogen, C_{1-6} alkyl, C_{3-6} cycloalkyl, phenyl, and phenyl (C_{1-4} alkyl)-; and

p is an integer of from 0 to 6, preferably from 0 to 4;

R^{12} and R^{13} are independently selected from hydrogen, C_{1-6} alkyl, C_{1-6} alkoxy, halo, phenyl, and C_{1-6} haloalkyl; and

15 R^{14} and R^{15} are independently selected from hydrogen and C_{1-4} alkyl with the proviso that the total number of carbon atoms in R^{14} and R^{15} is not more than 4.

Examples of anti-histamines include methapyrilene or loratadine.

20 Other suitable combinations include, for example, other anti-inflammatory agents eg. NSAIDs (eg. leukotriene antagonists, iNOS inhibitors, tryptase and elastase inhibitors, beta-2 integrin antagonists and adenosine 2a agonists)) or antiinfective agents (eg. antibiotics, antivirals).

25 The combinations referred to above may conveniently be presented for use in the form of a pharmaceutical composition and thus a pharmaceutical composition comprising a combination as defined above together with one or more pharmaceutically acceptable carriers and/or excipients represent a further aspect of the invention.

30 The individual compounds of such combinations may be administered either sequentially or simultaneously in separate or combined pharmaceutical composition.

Biological Test Methods

35

PDE 3, PDE 4B, PDE 5 Primary assay methods

The activity of the compounds can be measured in the assay methods shown below.

Preferred compounds of the invention are selective PDE4 inhibitors, i.e. they inhibit

40 PDE4 (e.g. PDE4B and/or PDE4D) more strongly than they inhibit PDE3 and/or more strongly than they inhibit PDE5.

Human recombinant PDE4B

Human recombinant PDE4B, in particular one splice variant thereof, is disclosed in WO 94/20079 and also M.M. McLaughlin et al., (A low K_m , rolipram-sensitive, cAMP-specific phosphodiesterase from human brain: cloning and expression of cDNA, biochemical characterisation of recombinant protein, and tissue distribution of mRNA, *J. Biol. Chem.*, 1993, 268, 6470-6476). Human recombinant PDE4B was expressed in the PDE-deficient yeast *Saccharomyces cerevisiae* strain GL62. 100,000 x g supernatant fractions of yeast cell lysates were used for PDE4B assays and inhibitor studies.

Inhibition of PDE 3, PDE 4B, or PDE 5 activity

The ability of compounds to inhibit catalytic activity at PDE4B (human recombinant), PDE3 (from bovine aorta) or PDE5 (human recombinant) was determined by Scintillation Proximity Assay (SPA) in 96-well format. Test compounds were preincubated at ambient temperature in Wallac Isoplates (code 1450-514) with PDE enzyme in 50mM Tris-HCl buffer pH 7.5, 8.3mM $MgCl_2$, 1.7mM EGTA, 0.05% (w/v) bovine serum albumin for 10-30 minutes. The enzyme concentration was adjusted so that no more than 20% hydrolysis of the substrate occurred in control wells without compound, during the incubation. For PDE3 and PDE4B assay [$5',8\text{-}^3H$]Adenosine 3',5'-cyclic phosphate (Amersham Pharmacia Biotech, code TRK.559) was added to give 0.05uCi per well and ~10nM final concentration. For PDE5 assay [8-^3H]Guanosine 3',5'-cyclic phosphate (Amersham Pharmacia Biotech, code TRK.392) was added to give 0.05uCi per well and ~36nM final concentration. Plates were mixed on an orbital shaker for 5 minutes and incubated at ambient temperature for 1 hour. Phosphodiesterase SPA beads (Amersham Pharmacia Biotech, code RPNQ 0150) were added (~1mg per well) to terminate the assay. Plates were sealed and shaken and allowed to stand at ambient temperature for 1 hour to allow the beads to settle. Bound radioactive product was measured using a WALLAC TRILUX 1450 Microbeta scintillation counter. For inhibition curves, 10 concentrations (1.5nM - 30uM) of each compound were assayed. Curves were analysed using ActivityBase and XLfit (ID Business Solutions Limited). Results were expressed as pIC_{50} values.

Biological Data obtained for some of the Examples (PDE4B inhibitory activity, either as one reading or as an average of ca. 2-6 readings) are as follows. Absolute accuracy is not possible, and the readings given are accurate only up to about ± 0.5 of a log unit:

Example	PDE4B pIC_{50}
6	8.1
10	8.2
12	7.9
14	7.6
23	8.2
24	8.2

Most or all of the Examples have PDE4B inhibitory activities in the range of pIC_{50} = about 5.5 to about 8.5 (± 0.5), more usually about 6 to about 8.5 (± 0.5). Most or many of the Examples have pIC_{50} = about 6.7 to about 8.4 (± 0.5).

5

Emesis: Many known PDE4 inhibitors cause emesis and/or nausea to greater or lesser extents (e.g. see Z. Huang et al., *Current Opinion in Chemical Biology*, 2001, 5: 432-438, see especially pages 433-434 and refs cited therein). Therefore, it would be preferable but not essential if a particular PDE4 inhibitory compound of the invention were to cause only limited or manageable emetic side-effects. Emetic side-effects can for example be measured by the emetogenic potential of the compound when administered to ferrets; for example one can measure the time to onset, extent, frequency and/or duration of vomiting, retching and/or writhing in ferrets after oral or parenteral administration of the compound. See for example A. Robichaud et al., "Emesis induced by inhibitors of [PDE IV] in the ferret", *Neuropharmacology*, 1999, 38, 289-297, erratum

10

15 *Neuropharmacology*, 2001, 40, 465-465.

Other side effects: Many known PDE4 inhibitors cause other side effects such as headache and other central nervous system (CNS-) mediated side effects; and/or gastrointestinal (GI) tract disturbances. Therefore, it would be preferable but not essential if a particular PDE4 inhibitory compound of the invention were to cause only limited or manageable side-effects in one or more of these side-effect categories.

20

25 All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.

EXAMPLES

The various aspects of the invention will now be described by reference to the following examples. These examples are merely illustrative and are not to be construed as a limitation of the scope of the present invention. In this section, "Intermediates" represent syntheses of intermediate compounds intended for use in the synthesis of the "Examples".

10 **Abbreviations used herein:**

	BEMP	2-t-butylimino-2-diethylamino-1,3-dimethylperhydro-1,3,2-diazaphosphazine
	DBU	1,8-Diazabicyclo[5.4.0]undec-7-ene
	DCM	dichloromethane
15	DMF	dimethyl formamide
	EtOAc	ethyl acetate
	Et ₂ O	diethyl ether
	EDC	1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
	HOBT	hydroxybenzotriazole
20	HATU	O-(7-Azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate
	HBTU	O-(Benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate
	HPLC	High performance liquid chromatography
	LCMS	liquid chromatography / mass spectroscopy
25	MeCN	acetonitrile
	MeOH	methanol
	NMR	nuclear magnetic resonance
	DIPEA	N,N-diisopropylethylamine
	SPE	solid phase extraction
30	TBTU	O-(Benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate
	THF	Tetrahydrofuran
	TRET	retention time
	TLC	thin layer chromatography
	Lawesson's reagent	2,4-bis(4-methoxyphenyl)-1,3-dithia-2,4-diphosphetane-2,4-disulphide
35	Burgess Reagent	(Methoxycarbonylsulphamoyl)triethylammonium hydroxide

Machine Methods used herein:

- 40 *LCMS (liquid chromatography / mass spectroscopy)*
 Waters ZQ mass spectrometer operating in positive ion electrospray mode, mass range 100-1000 amu.
 UV wavelength : 215-330nm

Column : 3.3cm x 4.6mm ID, 3 μ m ABZ+PLUS

Flow Rate : 3ml/min

Injection Volume : 5 μ l

Solvent A : 95% acetonitrile + 0.05% formic acid

5 Solvent B : 0.1% formic acid + 10mMolar ammonium acetate

Gradient : 0% A/0.7min, 0-100% A/3.5min, 100% A/1.1min, 100-0% A/0.2min

Mass directed autoprep HPLC

The prep column used was a Supelcosil ABZplus (10cm x 2.12cm)

10 UV wavelength : 200-320nm

Flow : 20ml/min

Injection Volume: 1ml

Solvent A : 0.1% formic acid

Solvent B : 95% acetonitrile + 5% formic acid

15 Gradient : 100% A/1min, 100-80% A/9min, 80-1% A/3.5min, 1% A/1.4min, 1-100%A/0.1min

Microwave

The CEM Discover Focused Microwave Synthesis system was used.

20

Intermediates and Examples

25 All reagents not detailed in the text below are commercially available from established suppliers such as Sigma-Aldrich.



Table of Intermediates

Intermediate Number	Name
1	Ethyl 4-chloro-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate
2	Ethyl 4-(cyclopentylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate
3	4-(Cyclopentylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid
4	N'-Acetyl-4-(Cyclopentylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carbohydrazide
5	4-(Cyclopentylamino)-1-ethyl-N'-[(methylsulfonyl)acetyl]-1H-pyrazolo[3,4-b]pyridine-5-carbohydrazide
6	Ethyl 4-(4-fluorophenylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate
7	4-(Cyclopentylamino)-1-ethyl-N-[methyl]-1H-pyrazolo[3,4-b]pyridine-5-carbohydrazide
8	Methanesulfonyl acetic acid hydrazide
9	Acetamidoxime


10	4-(Cyclopentylamino)-1-ethyl-N'-isobutyryl-1H-pyrazolo[3,4-b]pyridine-5-carbohydrazide
11	4-Chloro-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid
12	4-Chloro-1-ethyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)-1H-pyrazolo[3,4-b]pyridine
13	4-Chloro-1-ethyl-5-(5-isopropyl-1,3,4-oxadiazol-2-yl)-1H-pyrazolo[3,4-b]pyridine
14	5-(5-Tert-butyl-1,3,4-oxadiazol-2-yl)-4-chloro-1-ethyl-1H-pyrazolo[3,4-b]pyridine
15	4-Chloro-1-ethyl-5-{5-[(methylsulfonyl)methyl]-1,3,4-oxadiazol-2-yl}-1H-pyrazolo[3,4-b]pyridine
16	Ethyl 1-ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridine-5-carboxylate
17	1-Ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid
18	Tert-butyl 2-{[1-ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]carbonyl}hydrazinecarboxylate
19	1-Ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridine-5-carbohydrazide dihydrochloride
20	N'-(Cyclopropylcarbonyl)-1-ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridine-5-carbohydrazide
21	Tetrahydro-2H-pyran-4-amine = 4-Aminotetrahydropyran
21A	Tetrahydro-2H-pyran-4-amine hydrochloride = 4-aminotetrahydropyran hydrochloride
22	N'-Hydroxy-2-methoxyethanimidamide
23	2-(Dimethylamino)-N'-hydroxyethanimidamide
24	N'-Hydroxy-2-morpholin-4-ylethanimidamide
25	1-Acetyl-4-aminopiperidine hydrochloride
26	3-Methyloxetane-3-carboxylic acid
27	(4-Methylpiperazin-1-yl)acetic acid
28	(Isopropylamino)(oxo)acetic acid
29	1-Methyl-5-oxopyrrolidine-3-carboxylic acid
30	Tetrahydro-2H-pyran-4-carboxylic acid
31	Morpholin-4-ylacetic acid
32	Tert-butoxyacetic acid

Intermediate 1: Ethyl 4-chloro-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate

Prepared from commercially available 5-amino-1-ethyl pyrazole as described by G. Yu et. al. in *J. Med Chem.*, 2001, 44, 1025-1027:

**Intermediate 2: Ethyl 4-(cyclopentylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate**


Intermediate 1 (0.051g) and cyclopentyl amine (0.019g) were suspended in ethanol (2ml) and triethylamine (0.14ml) was added. The mixture was stirred under nitrogen and heated at 80°C for 16h. After cooling to room temperature, ethanol was removed by evaporation under a stream of nitrogen and the residue partitioned between DCM and water. The organic layer was loaded directly onto an SPE cartridge (silica, 5g) and eluted sequentially with; (i) DCM, (ii) DCM : Et₂O (2:1), (iii) DCM : Et₂O (1:1), (iv) Et₂O, (v) EtOAc and (vi) MeOH. Fractions containing desired material were combined and concentrated in vacuo to afford Intermediate 2 (0.074g). LCMS showed MH⁺ = 303; T_{RET} = 3.45min

Intermediate 3: 4-(Cyclopentylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid

A solution of Intermediate 2 (2.2g) in ethanol: water (95:5, 16.85ml) was treated with sodium hydroxide (1.2g) and heated at 50°C for 16h. The mixture was concentrated in vacuo and the residue re-dissolved in water (0.85ml). The solution was acidified to pH4


using acetic acid and the resultant white precipitate was collected by filtration and dried under vacuum to afford Intermediate 3 (1.9g). LCMS showed $MH^+ = 275$; $T_{RET} = 2.65\text{min}$

5 **Intermediate 4:** N'-Acetyl-4-(Cyclopentylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carbohydrazide



10 Intermediate 3 (0.066g), EDC (0.06g) and HOBT (0.035g) were suspended in DMF (2ml) and the mixture was stirred for 15 minutes. Acetic hydrazide (0.02g) was then added and the mixture stirred under nitrogen for 18h. Solvents were removed by concentration in vacuo and the residue partitioned between DCM and water. The layers were separated and the organic phase was washed with saturated aqueous sodium bicarbonate solution,
15 then concentrated and applied to an SPE cartridge (aminopropyl, 1g) which was eluted with methanol. Concentration in vacuo afforded Intermediate 4 (0.043g). LCMS showed $MH^+ = 331$; $T_{RET} = 2.38\text{min}$.


Intermediate 5: 4-(Cyclopentylamino)-1-ethyl-N'-[(methylsulfonyl)acetyl]-1H-pyrazolo[3,4-b]pyridine-5-carbohydrazide



20


Intermediate 3 (0.12g), EDC (0.12g) and HOBT (0.072g) were suspended in DMF (2ml) and stirred for 15 minutes. Intermediate 8 (0.082g) was then added and the mixture stirred under nitrogen for 18h. Reaction was incomplete so a further portion of Intermediate 8
25 was added (0.040g) and stirring continued for a further 66h. Solvents were removed in vacuo and the residue partitioned between DCM and water. The aqueous phase was further extracted with DCM and the combined organic layers applied to an SPE cartridge (silica, 5g) which was eluted sequentially with a gradient of Et₂O: MeOH (1:0, 9:1, 8:2, 7:3 and 6:4). Fractions containing desired material were combined and concentrated in
30 vacuo to afford Intermediate 5 (0.154g). LCMS showed $MH^+ = 409$; $T_{RET} = 2.42\text{min}$.

Intermediate 6: Ethyl 4-(4-fluorophenylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate



5 Intermediate 1 (0.051g) and 4-fluoroaniline (0.024g) were suspended in ethanol (2ml) and triethylamine (0.14ml) was added. The mixture was stirred under nitrogen and heated at 80°C for 16h. After cooling to room temperature, ethanol was removed by evaporation under a stream of nitrogen and the residue partitioned between DCM and water. The organic layer was loaded directly onto an SPE cartridge (silica, 5g) and eluted sequentially with; (i) DCM, (ii) DCM : Et₂O (2:1), (iii) DCM : Et₂O (1:1), (iv) Et₂O, (v) EtOAc, (vi) MeOH. Fractions containing desired material were combined and concentrated in vacuo to afford Intermediate 6 (0.077g). LCMS showed MH⁺ = 328; T_{RET} = 3.36min.


15 **Intermediate 7:** 4-(Cyclopentylamino)-1-ethyl-N-[methyl]-1H-pyrazolo[3,4-b]pyridine-5-carbohydrazide




Intermediate 3 (0.10g) was dissolved in DMF (2ml) and treated with HBTU (0.136g) and DIPEA (0.116g). A separate portion of Intermediate 3 (0.10g) was dissolved in DMF (2ml) and treated with EDC (0.096g) and HOBT (0.058g). The resultant suspensions were both stirred under nitrogen for 15min, then methyl hydrazine (0.017g) added to each and stirring continued under nitrogen for 18h. The mixtures were independently concentrated in vacuo and the residues partitioned between DCM and water. The organic layers were concentrated and each applied to an SPE cartridge (aminopropyl, 2g) which was eluted with methanol, followed by 10% ammonia in methanol. The two portions of Intermediate 7 thus afforded were combined (0.16g). LCMS showed MH⁺ = 303; T_{RET} = 2.22min.

Intermediate 8: Methanesulfonyl acetic acid hydrazide

Prepared from commercially available ethyl methylsulphonyl acetate as described by D. E. Bays et. al. in EP 50407 :




5

Intermediate 9: Acetamidoxime


Can be prepared from aqueous hydroxylamine and acetonitrile as described by J. J. Sahbari et. al. in WO 00032565.

10

Intermediate 10: 4-(Cyclopentylamino)-1-ethyl-N'-isobutyryl-1H-pyrazolo[3,4-b]pyridine-5-carbohydrazide

Intermediate 3 (0.060g), EDC (0.06g) and HOBT (0.035g) were suspended in DMF (2ml) and stirred under nitrogen for 15 minutes. Isobutyric acid hydrazide (0.027g) was then added and the mixture stirred under nitrogen for 18h. Solvents were removed in vacuo and the residue partitioned between DCM and water. The organic phase was washed with saturated aqueous sodium bicarbonate solution, then concentrated in vacuo and applied to an SPE cartridge (aminopropyl, 1g) which was eluted with methanol. Concentration in vacuo afforded Intermediate 10. LCMS showed $MH^+ = 359$; $T_{RET} = 2.70min$.


20

Intermediate 11: 4-Chloro-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid

A solution of Intermediate 1 (3.5g) in dioxane (28ml) was treated with potassium hydroxide (6.3g) as a solution in water (20ml). The mixture was stirred for 2h, then concentrated in vacuo, acidified to pH 3 with 2M aqueous hydrochloric acid and extracted with ethyl acetate. The layers were separated, the organic layer dried over sodium sulphate, then concentrated in vacuo to afford Intermediate 11 as a white solid (2.4g). LCMS showed $MH^+ = 226$; $T_{RET} = 2.62min$.


30

Intermediate 12: 4-Chloro-1-ethyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)-1H-pyrazolo[3,4-b]pyridine




5 Intermediate 11 (0.4g) was dissolved in thionyl chloride (3ml) and the mixture was heated at reflux (95°C) with stirring for 1h. After cooling to room temperature, excess thionyl chloride was removed by evaporation under reduced pressure and the resultant solid dissolved in anhydrous acetonitrile (2ml). This solution was added to a solution of acetic hydrazide (0.145g) and diisopropylethylamine (0.465ml) in anhydrous acetonitrile
10 (2ml), and the mixture stirred for a further 2h. The mixture was concentrated in vacuo and the residue treated directly with phosphorus oxychloride (4ml). The resultant solution was stirred and heated at reflux (120°C) for 0.5h, then allowed to cool and purified by Biotage (silica, 40g), eluting with cyclohexane : EtOAc (1:1) to afford Intermediate 12 (0.32g). LCMS showed $MH^+ = 264$; $T_{RET} = 2.55$ min.

Intermediate 13: 4-Chloro-1-ethyl-5-(5-isopropyl-1,3,4-oxadiazol-2-yl)-1H-pyrazolo[3,4-b]pyridine



20 Intermediate 11 (0.05g) was dissolved in thionyl chloride (1ml) and the mixture was heated at reflux (95°C) with stirring for 1h. After cooling to room temperature, excess thionyl chloride was removed by evaporation under reduced pressure and the resultant solid dissolved in anhydrous acetonitrile (0.5ml). This solution was added to a solution of isobutyric acid hydrazide (0.025g) and diisopropylethylamine (0.058ml) in anhydrous acetonitrile (1ml), and the mixture stirred for a further 1.5h. The mixture was
25 concentrated in vacuo and the residue treated directly with phosphorus oxychloride (2ml). The resultant solution was stirred and heated at reflux (120°C) for 2h, then allowed to cool and concentrated in vacuo. The residue was applied to an SPE cartridge (silica, 5g) which was eluted sequentially with a gradient of EtOAc : cyclohexane (i) 1:16, (ii) 1:8, (iii) 1:4, (iv) 1:2, (v) 1:1 and (vi) 1:0. Fractions containing desired material were
30 combined and concentrated in vacuo to afford Intermediate 13 (0.049g). LCMS showed $MH^+ = 292$; $T_{RET} = 2.96$ min.


Intermediate 14: 5-(5-Tert-butyl-1,3,4-oxadiazol-2-yl)-4-chloro-1-ethyl-1H-pyrazolo[3,4-b]pyridine



Intermediate 11 (0.40g) was dissolved in thionyl chloride (3ml) and the mixture was heated at reflux (95°C) with stirring for 1h. After cooling to room temperature, excess thionyl chloride was removed by evaporation under reduced pressure and the resultant solid dissolved in anhydrous acetonitrile (2ml). This solution was added to a solution of pivalic acid hydrazide (0.228g) and diisopropylethylamine (0.465ml) in anhydrous acetonitrile (2ml), and the mixture stirred for a further 1.5h. The mixture was concentrated in vacuo and the residue treated directly with phosphorus oxychloride (5ml). The resultant solution was stirred and heated at reflux (120°C) for 1.5h, then allowed to cool, concentrated in vacuo and purified by Biotage (silica, 40g), eluting with petroleum ether (40/60) : EtOAc (1:1) to afford Intermediate 14 (0.388g). LCMS showed MH^+ = 306; T_{RET} = 3.14 min.

15


Intermediate 15: 4-Chloro-1-ethyl-5-{5-[(methylsulfonyl)methyl]-1,3,4-oxadiazol-2-yl}-1H-pyrazolo[3,4-b]pyridine



Intermediate 11 (0.68g) was dissolved in thionyl chloride (4ml) and the mixture was heated at reflux (95°C) with stirring for 1h. After cooling to room temperature, excess thionyl chloride was removed by evaporation under reduced pressure and the resultant solid dissolved in anhydrous acetonitrile (3ml). This solution was added dropwise over 5 minutes to a solution of Intermediate 8 (0.504g) and diisopropylethylamine (0.787ml) in anhydrous acetonitrile (12ml), and the mixture then stirred for a further 1h. The mixture was concentrated in vacuo and the residue treated directly with phosphorus oxychloride (8ml). The resultant solution was stirred and heated at reflux (120°C) for 2.5h, then allowed to cool, concentrated in vacuo and purified by Biotage (silica, 40g), eluting first with petroleum ether (40/60) : EtOAc (2:1), then with petroleum ether (40/60) : EtOAc (1:1). Fractions containing desired material were combined, concentrated in vacuo and the residue further purified by trituration with diethyl ether to afford Intermediate 15 (0.41g). LCMS showed MH^+ = 342; T_{RET} = 2.46 min.


30

Intermediate 16: Ethyl 1-ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridine-5-carboxylate




- 5 Intermediate 1 (0.20g) and triethylamine (0.55ml) were suspended in ethanol (8ml) and 4-aminotetrahydropyran (Intermediate 21, 0.088g) was added. The mixture was stirred under nitrogen, heated at 80°C for 16h, then concentrated in vacuo. The residue was partitioned between DCM and water. The layers were separated and the organic layer was loaded directly onto an SPE cartridge (silica, 5g) which was eluted sequentially with; (i)
- 10 DCM, (ii) DCM : Et₂O (2:1), (iii) DCM : Et₂O (1:1), (iv) Et₂O and (v) EtOAc. Fractions containing desired material were combined and concentrated in vacuo to afford Intermediate 16 (0.21g). LCMS showed MH⁺ = 319; T_{RET} = 2.93min.

15 **Intermediate 17: 1-Ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid**



- A solution of Intermediate 16 (0.21g) in ethanol : water (95:5, 10ml) was treated with sodium hydroxide (0.12g). The mixture was heated at 50°C for 8h, then concentrated in vacuo, dissolved in water and acidified to pH 4 with acetic acid. The resultant white solid
- 20 was removed by filtration and dried under vacuum to afford Intermediate 17 as an off-white solid (0.16g). LCMS showed MH⁺ = 291; T_{RET} = 2.11min.


Intermediate 18: Tert-butyl 2-[[1-ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]carbonyl]hydrazinecarboxylate



- 25 A suspension of Intermediate 17 (1.48g), EDC (1.34g) and HOBt (0.83g) in DMF (20ml) was stirred at room temperature for 30min. t-Butyl carbazate (0.68g) was then


added and stirring continued under nitrogen for a further 66h. The mixture was concentrated in vacuo and the residue divided into two portions for purification. Each portion was applied to an SPE cartridge (aminopropyl, 10g) which was eluted with methanol and the combined eluents were concentrated in vacuo. Further purification was carried out by Biotage (silica, 40g), eluting with cyclohexane : ethyl acetate (1:4). Fractions containing desired material were combined and concentrated in vacuo to afford Intermediate 18 (1.39g). LCMS showed $MH^+ = 405$; $T_{RET} = 2.64min$.

Intermediate 19: 1-Ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridine-5-carbohydrazide dihydrochloride




Intermediate 18 (1.39g) was treated with a 4M solution of hydrochloric acid in dioxane (8ml) and the mixture stirred under nitrogen for 1h. Concentration in vacuo afforded Intermediate 19 as a white solid (1.17g). LCMS showed $MH^+ = 305$; $T_{RET} = 2.04min$.

Intermediate 20: N'-(Cyclopropylcarbonyl)-1-ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridine-5-carbohydrazide




A solution of Intermediate 19 (0.045g) in THF (2ml) was treated with DIPEA (0.045ml), then with cyclopropylcarbonyl chloride (0.013g) and stirred at room temperature for 16h. The mixture was concentrated in vacuo and the residue partitioned between dichloromethane and water. The layers were separated and the organic layer concentrated in vacuo, then applied to an SPE cartridge (aminopropyl, 1g). The column was eluted with methanol to afford Intermediate 20 as a white solid (0.02g). LCMS showed $MH^+ = 373$; $T_{RET} = 2.15min$.

Intermediate 21: 4-Aminotetrahydropyran



Commercially available from Combi-Blocks Inc., 7949 Silverton Avenue, Suite 915, San Diego, CA 92126 (CAS 38041-19-9)

Intermediate 21A: Tetrahydro-2H-pyran-4-amine hydrochloride = 4-Aminotetrahydropyran hydrochloride




Step 1: *N,N*-dibenzyltetrahydro-2H-pyran-4-amine

Dibenzylamine (34.5g) and acetic acid (6.7ml) were added to a stirred solution of tetrahydro-4H-pyran-4-one (16.4g, commercially available from e.g. Aldrich) in dichloromethane (260ml) at 0 °C to 5 °C. After 2.5h at 0 °C to 5 °C, sodium triacetoxyborohydride (38.9g) was added portionwise, and the mixture was allowed to warm to room temperature. After stirring at room temperature overnight, the reaction mixture was washed successively with 2M-sodium hydroxide (200ml and 50ml), water (2 x 50ml) and brine (50ml), then dried and evaporated to give a yellow oil (45g). This oil was stirred with methanol (50ml) at 4 °C for 30min to give the product as a white solid (21.5g). LCMS showed $MH^+ = 282$; $T_{RET} = 1.98$ min.


Step 2: Tetrahydro-2H-pyran-4-amine hydrochloride

N,N-dibenzyltetrahydro-2H-pyran-4-amine (20.5g) was dissolved in ethanol (210ml) and hydrogenated over 10% palladium on carbon catalyst (4g) at 100 psi for 72h at room temperature. The reaction mixture was filtered and the filtrate was adjusted to pH 1 with 2M-hydrogen chloride in diethyl ether. Evaporation of solvents gave a solid which was triturated with diethyl ether to give the product as a white solid (9.23g). 1H NMR (400MHz, d_6 -DMSO, δ ppm) 8.24 (br. s, 3H), 3.86 (dd, 12, 4Hz, 2H), 3.31 (dt, 2, 12Hz, 2H), 3.20 (m, 1H), 1.84 (m, 2H), 1.55 (dq, 4, 12Hz, 2H).

Intermediate 22: *N'*-Hydroxy-2-methoxyethanimidamide




A solution of methoxyacetonitrile (12.26g) in ethanol (220ml) was treated with hydroxylamine hydrochloride (11.95g) followed by potassium carbonate (22.9g) and heated under reflux for 2 days. The mixture was concentrated in vacuo, then partitioned between ethylacetate and water. The organic layer was concentrated in vacuo to afford Intermediate 22 as a colourless liquid (7.6g). 1H NMR ($CDCl_3$) 7.16 (3H, s), 7.67 (s, 2H), 9.32 (brs, 2H), 13.08 (1H, s).

Intermediate 23: 2-(Dimethylamino)-N'-hydroxyethanimidamide

Can be prepared in an analogous manner to Intermediate 9, starting from dimethylamino acetonitrile.

5

Intermediate 24: N'-Hydroxy-2-morpholin-4-ylethananimidamide



Can be prepared in an analogous manner to Intermediate 9, starting from morpholino acetonitrile (itself commercially available from TCI America, 9211 North Harborsgate Street, Portland, OR 97203, USA).

10

Intermediate 25: 1-Acetyl-4-aminopiperidine hydrochloride

Prepared from commercially available N1-benzyl-4-aminopiperidine as described by Yamada *et. al.* In WO 00/42011:


15

**Intermediate 26: 3-Methyloxetane-3-carboxylic acid**

20


Can be prepared by oxidation of 3-Methyl-3-oxetanemethanol (commercially available from e.g. Fluka, CAS 3143-02-0) according to the procedure described by H. Fiege *et. al.* in DE3618142.

25


Intermediate 27: (4-Methylpiperazin-1-yl)acetic acid

30


Commercially available from ChemPacific USA Sales Marketing and Research Center, 6200 Freeport Centre, Baltimore, MD 21224, USA (CAS 54699-92-2).

Intermediate 28: (Isopropylamino)(oxo)acetic acid


- 5 Commercially available from Austin Chemical Company, Inc., 1565 Barclay Blvd., Buffalo Grove, IL 60089, USA (CAS 3338-22-5)

Intermediate 29: 1-Methyl-5-oxopyrrolidine-3-carboxylic acid


- 10 Commercially available from MicroChemistry-RadaPharma, Shosse Entusiastov 56, Moscow 111123, Russia (CAS 42346-68-9).

Intermediate 30: Tetrahydro-2H-pyran-4-carboxylic acid

- 15 Commercially available from Combi-Blocks Inc., 7949 Silverton Avenue, Suite 915, San Diego, CA 92126, USA (CAS 5337-03-1)

Intermediate 31: Morpholin-4-ylacetic acid

- 20 Can be prepared from ethyl bromoacetate as described by Z. Dega-Szafran et. al. in *J. Molecular Structure*, 2001, 560, 261-273.

Intermediate 32: Tert-butoxyacetic acid

- 25 A suspension of sodium t-butoxide (24.1g) in t-butanol (150ml) was cooled in a water bath and treated drop-wise with a solution of chloroacetic acid (11.4g) in t-butanol (30ml). The mixture was heated under reflux for 5h then concentrated in vacuo. The resultant white solid was dried in vacuo for 16h then water (100ml) was added and the mixture was filtered. The filtrate was treated with diethyl ether (150ml), then cooled in an ice bath, stirred and acidified to pH1 with 2N sulphuric acid. The layers were separated and the aqueous layer was further extracted with diethyl ether. The combined organic extracts were dried (MgSO₄) and concentrated in vacuo to afford Intermediate 32 (11.1g).
30 ¹H NMR (400MHz, CDCl₃, δppm) 1.27 (9H, s), 4.04 (2H, s).


Table of Examples

Example Number	Name
1	N-Cyclopentyl-1-ethyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine
2	N-Cyclopentyl-1-ethyl-5-{5-[(methylsulfonyl)methyl]-1,3,4-oxadiazol-2-yl}-1H-pyrazolo[3,4-b]pyridin-4-amine
3	N-Cyclopentyl-1-ethyl-5-(5-isopropyl-1,3,4-oxadiazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine
4	N-Cyclopentyl-1-ethyl-5-(5-methyl-1,3,4-thiadiazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine
5	N-Cyclopentyl-1-ethyl-5-{5-[(methylsulfonyl)methyl]-1,3,4-thiadiazol-2-yl}-1H-pyrazolo[3,4-b]pyridin-4-amine
6	N-Cyclopentyl-1-ethyl-5-(5-isopropyl-1,3,4-thiadiazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine
7	1-Ethyl-N-(4-fluorophenyl)-5-(3-methyl-1,2,4-oxadiazol-5-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine
8	N-Cyclopentyl-5-(1,3-dimethyl-1H-1,2,4-triazol-5-yl)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-4-amine
9	1-Ethyl-5-(5-isopropyl-1,3,4-oxadiazol-2-yl)-N-tetrahydro-2H-pyran-4-yl-1H-pyrazolo[3,4-b]pyridin-4-amine
10	N-Cyclohexyl-1-ethyl-5-(5-isopropyl-1,3,4-oxadiazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine
11	1-Ethyl-N-isobutyl-5-(5-isopropyl-1,3,4-oxadiazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine
12	1-Ethyl-N-isobutyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine
13	N-Cyclohexyl-1-ethyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine
14	1-Ethyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)-N-tetrahydro-2H-pyran-4-yl-1H-pyrazolo[3,4-b]pyridin-4-amine
15	N-[(1R)-1,2-dimethylpropyl]-1-ethyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine
16	N-[(1S)-1,2-dimethylpropyl]-1-ethyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine
17	5-(5-Tert-butyl-1,3,4-oxadiazol-2-yl)-1-ethyl-N-tetrahydro-2H-pyran-4-yl-1H-pyrazolo[3,4-b]pyridin-4-amine
18	5-(5-Tert-butyl-1,3,4-oxadiazol-2-yl)-N-cyclohexyl-1-ethyl-1H-pyrazolo[3,4-b]pyridin-4-amine
19	5-(5-Tert-butyl-1,3,4-oxadiazol-2-yl)-N-cyclopentyl-1-ethyl-1H-pyrazolo[3,4-

	b]pyridin-4-amine
20	5-(5-Tert-butyl-1,3,4-oxadiazol-2-yl)-1-ethyl-N-isobutyl-1H-pyrazolo[3,4-b]pyridin-4-amine
21	5-(5-Tert-butyl-1,3,4-oxadiazol-2-yl)-N-[(1S)-1,2-dimethylpropyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridin-4-amine
22	5-(5-Tert-butyl-1,3,4-oxadiazol-2-yl)-N-[(1R)-1,2-dimethylpropyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridin-4-amine
23	1-Ethyl-5-{5-[(methylsulfonyl)methyl]-1,3,4-oxadiazol-2-yl}-N-tetrahydro-2H-pyran-4-yl-1H-pyrazolo[3,4-b]pyridin-4-amine
24	N-Cyclohexyl-1-ethyl-5-{5-[(methylsulfonyl)methyl]-1,3,4-oxadiazol-2-yl}-1H-pyrazolo[3,4-b]pyridin-4-amine
25	1-Ethyl-N-isobutyl-5-{5-[(methylsulfonyl)methyl]-1,3,4-oxadiazol-2-yl}-1H-pyrazolo[3,4-b]pyridin-4-amine
26	N-[(1S)-1,2-dimethylpropyl]-1-ethyl-5-{5-[(methylsulfonyl)methyl]-1,3,4-oxadiazol-2-yl}-1H-pyrazolo[3,4-b]pyridin-4-amine
27	N-[(1R)-1,2-dimethylpropyl]-1-ethyl-5-{5-[(methylsulfonyl)methyl]-1,3,4-oxadiazol-2-yl}-1H-pyrazolo[3,4-b]pyridin-4-amine
28	1-Ethyl-5-(3-methyl-1,2,4-oxadiazol-5-yl)-N-tetrahydro-2H-pyran-4-yl-1H-pyrazolo[3,4-b]pyridin-4-amine
29	1-Ethyl-5-[3-(methoxymethyl)-1,2,4-oxadiazol-5-yl]-N-tetrahydro-2H-pyran-4-yl-1H-pyrazolo[3,4-b]pyridin-4-amine
30	5-{3-[(Dimethylamino)methyl]-1,2,4-oxadiazol-5-yl}-1-ethyl-N-tetrahydro-2H-pyran-4-yl-1H-pyrazolo[3,4-b]pyridin-4-amine
31	1-Ethyl-5-[3-(morpholin-4-ylmethyl)-1,2,4-oxadiazol-5-yl]-N-tetrahydro-2H-pyran-4-yl-1H-pyrazolo[3,4-b]pyridin-4-amine
32	5-(5-Cyclopropyl-1,3,4-oxadiazol-2-yl)-1-ethyl-N-tetrahydro-2H-pyran-4-yl-1H-pyrazolo[3,4-b]pyridin-4-amine
33	N-(1-Acetylpiperidin-4-yl)-1-ethyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine
34	1-Ethyl-5-[5-(3-methyloxetan-3-yl)-1,3,4-oxadiazol-2-yl]-N-tetrahydro-2H-pyran-4-yl-1H-pyrazolo[3,4-b]pyridin-4-amine
35	1-Ethyl-5-{5-[(4-methylpiperazin-1-yl)methyl]-1,3,4-oxadiazol-2-yl}-N-tetrahydro-2H-pyran-4-yl-1H-pyrazolo[3,4-b]pyridin-4-amine
36	5-[1-Ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]-N-isopropyl-1,3,4-oxadiazole-2-carboxamide
37	4-{5-[1-Ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}-1-methylpyrrolidin-2-one
38	1-Ethyl-N-tetrahydro-2H-pyran-4-yl-5-(5-tetrahydro-2H-pyran-4-yl-1,3,4-oxadiazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine
39	1-Ethyl-5-[5-(morpholin-4-ylmethyl)-1,3,4-oxadiazol-2-yl]-N-tetrahydro-2H-pyran-4-yl-1H-pyrazolo[3,4-b]pyridin-4-amine
40	5-[5-(Tert-butoxymethyl)-1,3,4-oxadiazol-2-yl]-1-ethyl-N-tetrahydro-2H-pyran-4-yl-1H-pyrazolo[3,4-b]pyridin-4-amine

4i	Methyl 2-[1-ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,3-oxazole-4-carboxylate
----	---

Example 1: N-Cyclopentyl-1-ethyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine



Example 1 $R^Y = \text{Me}$


5

Intermediate 4 (0.043g) was dissolved in acetonitrile (2ml) then treated with phosphorous oxychloride (0.101g) and stirred under nitrogen and heated at 90°C for 2h. The mixture was concentrated in vacuo and the residue partitioned between DCM and saturated aqueous sodium bicarbonate solution. The organic layer was concentrated in vacuo and applied to an SPE cartridge (aminopropyl, 1g), which was eluted with methanol. Concentration in vacuo afforded Example 1 (0.032g). LCMS showed $MH^+ = 313$; $T_{RET} = 3.13\text{min}$.

15 Similarly prepared but with an extended reaction time (see table) was:

	R^Y	Starting material	Reaction time	MH^+ ion	$T_{RET}(\text{min})$
Example 2		Intermediate 5	3h	391	2.88

20 **Example 3:** N-Cyclopentyl-1-ethyl-5-(5-isopropyl-1,3,4-oxadiazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine




25 Intermediate 10 was dissolved in acetonitrile (2ml) then treated with phosphorous oxychloride (0.101g) and stirred under nitrogen at 90°C for 3.5h. The mixture was concentrated in vacuo and the residue partitioned between DCM and saturated aqueous

sodium bicarbonate solution. The organic layer was concentrated in vacuo and the residue applied to a SPE cartridge (silica, 5g), which was eluted with cyclohexane : Et₂O (1:2). Fractions containing desired material were combined and concentrated in vacuo to afford Example 3 (0.034g). LCMS showed MH⁺ = 341; T_{RET} = 3.39min.

5


Example 4: N-Cyclopentyl-1-ethyl-5-(5-methyl-1,3,4-thiadiazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine



10 A solution of Intermediate 4 (0.09g) in acetonitrile (5ml) was stirred under nitrogen and treated with Lawesson's reagent (0.116g). The mixture was heated at 65°C for 16h, then concentrated in vacuo. The residue was applied to an SPE cartridge (silica, 5g) and eluted with a gradient of cyclohexane : Et₂O (1:2 then 1:3, 1:4, 1:5, 0:1). Fractions containing desired material were combined and concentrated in vacuo. Further purification was achieved using mass directed autoprep HPLC to afford Example 4 (0.002g). LCMS showed MH⁺ = 339; T_{RET} = 3.23min.

15

Example 5: N-Cyclopentyl-1-ethyl-5-{5-[(methylsulfonyl)methyl]-1,3,4-thiadiazol-2-yl}-1H-pyrazolo[3,4-b]pyridin-4-amine




20

A solution of Intermediate 5 (0.07g) in acetonitrile (3ml) was stirred under nitrogen and treated with Lawesson's reagent (0.085g). The mixture was heated at 65°C for 136h, then concentrated in vacuo. The residue was partitioned between DCM and water and the organic layer concentrated in vacuo. Further purification was achieved using mass directed autoprep HPLC to afford Example 5 (0.008g). LCMS showed MH⁺ = 407; T_{RET} = 2.98min.


25

Example 6: N-Cyclopentyl-1-ethyl-5-(5-isopropyl-1,3,4-thiadiazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine




5 Intermediate 10 was dissolved in acetonitrile (5ml) then treated with Lawesson's reagent (0.125g) and heated under nitrogen at 65°C for 66h. Volatiles were removed in vacuo and the residue was purified by mass directed autoprep HPLC to afford Example 6. LCMS showed $MH^+ = 357$; $T_{RET} = 3.59$ min.

10 **Example 7:** 1-Ethyl-N-(4-fluorophenyl)-5-(3-methyl-1,2,4-oxadiazol-5-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine



15 A solution of Intermediate 6 (0.04g) in ethanol (1ml) was stirred over powdered 4Å molecular sieves (0.290g) and treated with Intermediate 9 (0.045g), followed by sodium ethoxide (0.020g). The mixture was heated under reflux for 18h, then cooled and filtered. Following concentration of the filtrate in vacuo, the residue was applied to an SPE cartridge (silica, 5g) which was eluted with cyclohexane : Et₂O (1:1). Fractions containing desired material were combined and concentrated in vacuo to afford Example 7 (0.017g). LCMS showed $MH^+ = 339$; $T_{RET} = 3.23$ min.


20 **Example 8:** N-Cyclopentyl-5-(1,3-dimethyl-1H-1,2,4-triazol-5-yl)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-4-amine



25 A solution of Intermediate 7 (0.06g) in ethanol (2ml) was treated with triethylamine (0.101g), followed by methyl acetimidate hydrochloride (0.033g) and the mixture heated under reflux (80°C) for 42h. Reaction was incomplete so a further portion of methyl acetimidate hydrochloride (0.033g) was added and stirring continued under reflux for 6 days. The mixture was concentrated in vacuo and the residue partitioned between DCM


and 2M aqueous HCl. The organic layer was concentrated in vacuo and purified by mass directed autoprep to afford Example 8 (0.003g). LCMS showed $MH^+ = 326$; $T_{RET} = 2.66$ min.

5 **Example 9:** 1-Ethyl-5-(5-isopropyl-1,3,4-oxadiazol-2-yl)-N-tetrahydro-2H-pyran-4-yl-1H-pyrazolo[3,4-b]pyridin-4-amine



Intermediate 13 (0.016g) was dissolved in anhydrous acetonitrile (1ml).
10 4-Aminotetrahydropyran hydrochloride (Intermediate 21A, 0.008g) was then added, followed by diisopropylethyl amine (0.05ml) and the mixture was stirred under nitrogen at 75°C for 19h. A further portion of 4-aminotetrahydropyran (0.002g) was added and stirring continued at 85°C for 16h. The mixture was concentrated in vacuo and partitioned between DCM and water. The organic phase was concentrated in vacuo and applied to an
15 SPE cartridge (silica, 1g), which was eluted sequentially with a gradient of EtOAc: cyclohexane (i) 1:8, (ii) 1:4, (iii) 1:2, (iv) 1:1 and (v) 1:0. Fractions containing desired material were combined and concentrated in vacuo to afford Example 9 (0.013g). LCMS showed $MH^+ = 357$; $T_{RET} = 2.89$ min.


20 **Example 10:** N-cyclohexyl-1-ethyl-5-(5-isopropyl-1,3,4-oxadiazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine



Example 10 $NHR^3 =$


Intermediate 13 (0.016g, 0.055 mmol) was dissolved in anhydrous acetonitrile (1ml).
25 Cyclohexyl amine (0.007ml, 0.061 mmol) was then added, followed by diisopropylethyl amine (0.05ml, 0.29 mmol) and the mixture was stirred under nitrogen at 75°C for 16h. The mixture was concentrated in vacuo and partitioned between DCM and water. The organic phase was concentrated in vacuo and applied to an SPE cartridge (silica, 1g), which was eluted sequentially with a gradient of EtOAc: cyclohexane (i) 1:16, (ii) 1:8,
30 (iii) 1:4, (iv) 1:2 and (v) 1:1. Fractions containing desired material were combined and concentrated in vacuo to afford Example 10 (0.015g). LCMS showed $MH^+ = 355$; $T_{RET} = 3.59$ min.


Similarly prepared using the same or similar number of moles of reagents and volumes of solvents was the following:

	NHR ³	Starting amine	MH ⁺ ion	T _{RET} (min)
Example 11		Isobutyl amine	329	3.40

5

Example 12: 1-Ethyl-N-isobutyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine



Example 12 R^Y = Me, NHR³ = 







10

Intermediate 12 (0.026g, 0.1 mmol) was dissolved in ethanol (1.5ml) and treated with a solution of isobutylamine (0.007g, 0.1 mmol), also in ethanol (1ml). The mixture was then treated with diisopropylethyl amine (0.075 ml, 0.4 mmol, 4 mole equivalents) and stirred at 75°C for 16h. The mixture was concentrated in vacuo and applied to an SPE cartridge (silica, 0.5g) which was eluted sequentially with (i) chloroform, (ii) Et₂O and (iii) methanol. Fractions containing desired material were combined and concentrated in vacuo to afford Example 12 (0.024g). LCMS showed MH⁺ = 301; T_{RET} = 2.90min

15

Similarly prepared using the same or similar number of moles of reagents and volumes of solvents were the following:


20

	R ^Y	NHR ³	Starting material	Amine reagent	MH ⁺ ion	T _{RET} (min)
Example 13	Me		Intermediate 12	Cyclohexylamine	327	3.12
Example 14	Me		Intermediate 12	4-Amino tetrahydropyran	329	2.49
Example 15	Me		Intermediate 12	(R)-(-)-3-methyl-2-butylamine	315	3.00
Example 16	Me		Intermediate 12	(S)-(-)-3-methyl-2-butylamine	315	3.00
Example 17	^t Bu		Intermediate 14	4-Amino tetrahydropyran	371	2.99
Example 18	^t Bu		Intermediate 14	Cyclohexylamine	369	3.64

Example 19	^t Bu		Intermediate 14	Cyclopentylamine	355	3.48
Example 20	^t Bu		Intermediate 14	Isobutylamine	343	3.43
Example 21	^t Bu		Intermediate 14	(S)-(-)-3-methyl-2-butylamine	357	3.53
Example 22	^t Bu		Intermediate 14	(R)-(-)-3-methyl-2-butylamine	357	3.53
Example 23			Intermediate 15	4-Amino tetrahydropyran	407	2.44
Example 24			Intermediate 15	Cyclohexylamine	405	3.00
Example 25			Intermediate 15	Isobutylamine	379	2.81
Example 26			Intermediate 15	(S)-(-)-3-methyl-2-butylamine	393	2.90
Example 27			Intermediate 15	(R)-(-)-3-methyl-2-butylamine	393	2.91

Example 28: 1-Ethyl-5-(3-methyl-1,2,4-oxadiazol-5-yl)-N-tetrahydro-2H-pyran-4-yl-1H-pyrazolo[3,4-b]pyridin-4-amine

5



Example 28 $R^X = \text{Me}$

10 A solution of Intermediate 16 (0.05g, 0.157 mmol) in ethanol (2ml) was stirred over powdered 4Å molecular sieves (0.30g) and treated with a solution of Intermediate 9 (0.059g, 0.8 mmol) and sodium ethoxide (0.027g, 0.4 mmol) in ethanol (1ml). The mixture was heated at reflux for 18h under nitrogen, then cooled and filtered. Following concentration of the filtrate in vacuo, the residue was applied to an SPE cartridge (silica, 5g) which was eluted with cyclohexane : EtOAc (1:1). Fractions containing desired material were combined and concentrated in vacuo to afford Example 28 (0.024g). LCMS showed $MH^+ = 329$; $T_{RET} = 2.86$ min.


15

Similarly prepared using the same or similar number of moles of reagents and volumes of solvents were the following:

	R ^X	Starting Amidoxime	MH ⁺ ion	T _{RET} (min)
Example 29	CH ₂ OMe	Intermediate 22	359	2.78

5

Example 30: 5-{3-[(Dimethylamino)methyl]-1,2,4-oxadiazol-5-yl}-1-ethyl-N-tetrahydro-2H-pyran-4-yl-1H-pyrazolo[3,4-b]pyridin-4-amine




10

A solution of Intermediate 16 (0.05g) in ethanol (2ml) was stirred over powdered 4Å molecular sieves (0.30g) and treated with a solution of Intermediate 23 (0.094g) and sodium ethoxide (0.027g) in ethanol (1ml). The mixture was heated at reflux for 18h under nitrogen, then cooled and filtered. Following concentration of the filtrate in vacuo, the residue was applied to an SPE cartridge (silica, 5g) which was eluted with 2-5% methanol in DCM. Fractions containing desired material were combined and concentrated in vacuo, then applied to a further SPE cartridge (aminopropyl, 1g) which was eluted with methanol to afford Example 30 (0.02g). LCMS showed MH⁺ = 372; T_{RET} = 2.10 min.

20

Example 31: 1-Ethyl-5-[3-(morpholin-4-ylmethyl)-1,2,4-oxadiazol-5-yl]-N-tetrahydro-2H-pyran-4-yl-1H-pyrazolo[3,4-b]pyridin-4-amine




25

A solution of Intermediate 16 (0.05g) in ethanol (2ml) was stirred over powdered 4Å molecular sieves (0.30g) and treated with a solution of Intermediate 24 (0.128g) and sodium ethoxide (0.027g) in ethanol (1ml). The mixture was heated at reflux for 18h under nitrogen, then cooled and filtered. Following concentration of the filtrate in vacuo,

the residue was applied to an SPE cartridge (silica, 5g) which was eluted with 2-5% methanol in DCM. Fractions containing desired material were combined and concentrated in vacuo to afford Example 31 (0.025g). LCMS showed $MH^+ = 415$; $T_{RET} = 2.46$ min.


5

Example 32: 5-(5-Cyclopropyl-1,3,4-oxadiazol-2-yl)-1-ethyl-N-tetrahydro-2H-pyran-4-yl-1H-pyrazolo[3,4-b]pyridin-4-amine




10 A solution of Intermediate 20 (0.020g) in THF (0.2ml) was treated with Burgess reagent (0.026g) and heated in a microwave at 120°C (100W) for 5min. The mixture was concentrated by evaporation under a stream of nitrogen and the residue applied to an SPE cartridge (silica, 1g) which was eluted with 2% methanol in DCM to afford Example 32 as a white solid (0.014g). LCMS showed $MH^+ = 355$; $T_{RET} = 2.78$ min.

15 **Example 33:** N-(1-Acetylpiperidin-4-yl)-1-ethyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine




20 Intermediate 12 (0.03g) was dissolved in acetonitrile (2ml) and treated with DIPEA (0.1ml) and Intermediate 25 (0.022g). The mixture was stirred at 85°C for 18h then concentrated in vacuo and partitioned between DCM and water. The layers were separated and the organic layer concentrated in vacuo, then purified by mass directed autoprep HPLC to afford Example 33 (0.01g). LCMS showed $MH^+ = 370$; $T_{RET} = 2.48$ min.

Example 34: 1-Ethyl-5-[5-(3-methyloxetan-3-yl)-1,3,4-oxadiazol-2-yl]-N-tetrahydro-2H-pyran-4-yl-1H-pyrazolo[3,4-b]pyridin-4-amine



Example 34 R^Y =




- 5 A solution of Intermediate 19 (0.05g, 0.133 mmol), TBTU (0.045g, 0.14 mmol) and DIPEA (0.1ml, ca. 0.5 mmol) in DMF (1ml) was stirred at room temperature under nitrogen for 5 min. A solution of Intermediate 26 (0.024g, 0.21 mmol) in DMF (1ml) was then added and stirring continued for 18h. Reaction was found to be incomplete after this time so a further portion of Intermediate 26 (0.012g, 0.10 mmol) was added and stirring continued under nitrogen for a further 18h. The mixture was concentrated in vacuo then the residue applied to an SPE cartridge (aminopropyl, 2g), which was eluted with methanol (2x3ml). Fractions containing desired material were concentrated in vacuo. The partially purified intermediate was taken forward without further characterisation and was dissolved in THF (0.5ml) then treated with Burgess reagent (0.025g, ca. 0.1 mmol).
- 15 The mixture was heated under microwave conditions at 120°C (120W) for 5 min. The mixture was then concentrated in vacuo and purified by mass directed autoprep HPLC to afford Example 34 (0.006g). LCMS showed MH⁺ = 385; T_{RET} = 2.65min.

20 Similarly prepared using the same or similar number of moles of reagents and volumes of solvents were the following:

	R ^Y	Starting Acid	MH ⁺ ion	T _{RET} (min)
Example 35		Intermediate 27	427	2.14
Example 36		Intermediate 28	400	2.87
Example 37		Intermediate 29	412	2.39

Example 38: 1-Ethyl-N-(tetrahydro-2H-pyran-4-yl)-5-[5-(tetrahydro-2H-pyran-4-yl)-1,3,4-oxadiazol-2-yl]-1H-pyrazolo[3,4-b]pyridin-4-amine




- 5 A solution of Intermediate 19 (0.05g, 0.133 mmol), TBTU (0.045g, 0.14 mmol) and DIPEA (0.1ml, ca. 0.5 mmol) in DMF (1ml) was stirred at room temperature under nitrogen for 5 min. A solution of Intermediate 30 (0.018g, 0.14 mmol) in DMF (1ml) was then added and stirring continued for 18h. Reaction was found to be incomplete after this time so a further portion of Intermediate 30 (0.009g, 0.07 mmol) was added and stirring.
- 10 continued under nitrogen for a further 18h. The mixture was concentrated in vacuo then the residue applied to an SPE cartridge (aminopropyl, 2g), which was eluted with methanol (2x3ml). Fractions containing desired material were concentrated in vacuo. The partially purified intermediate was taken forward without further characterisation and was dissolved in THF (0.5ml) then treated with Burgess reagent (0.025g, ca. 0.1 mmol). The
- 15 mixture was heated under microwave conditions at 120°C (120W) for 5 min. Reaction appeared incomplete so a further portion of Burgess Reagent (0.012g, ca. 0.05 mmol) was added and the mixture heated under microwave conditions at 140°C (120W) for a further 10 min. The mixture was then concentrated in vacuo and purified by mass directed autoprep HPLC to afford Example 38 (0.006g). LCMS showed $MH^+ = 399$; $T_{RET} =$
- 20 2.64min.

Similarly prepared using the same or similar number of moles of reagents and volumes of solvents were the following:


	R^Y	Starting Acid	MH^+ ion	T_{RET} (min)
Example 39		Intermediate 31	414	2.44
Example 40	CH_2O^tBu	Intermediate 32	401	2.98

Example 41: Methyl 2-[1-ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,3-oxazole-4-carboxylate



5

The compound of Example 41 was synthesised using the following route, reagents and solvents:



PCT Application
PCT/EP2003/014867



This Page is inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☒ BLACK BORDERS

☒ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

☒ FADED TEXT OR DRAWING

☐ BLURED OR ILLEGIBLE TEXT OR DRAWING

☒ SKEWED/SLANTED IMAGES

☐ COLORED OR BLACK AND WHITE PHOTOGRAPHS

☐ GRAY SCALE DOCUMENTS

☐ LINES OR MARKS ON ORIGINAL DOCUMENT

☐ REPERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images
problems checked, please do not report the
problems to the IFW Image Problem Mailbox**